

Chapter I
Overview
Chapter Contents

Table Number	Contents
I-1	Estimated New Cancer Cases and Deaths for 2005
I-2	53-Year Trends in US Cancer Death Rates
I-3	Summary of Changes in Cancer Incidence and Mortality 1950-2002 and 5-Year Relative Survival Rates
I-4	Age-Adjusted SEER Incidence and US Death Rates and 5-Year Relative Survival Rates, All Races
I-5	Age-Adjusted SEER Incidence and US Death Rates and 5-Year Relative Survival Rates, Whites
I-6	Age-Adjusted SEER Incidence and US Death Rates and 5-Year Relative Survival Rates, Blacks
I-7	SEER Incidence and US Mortality Trends by Primary Cancer Site and Sex, All Races
I-8	SEER Incidence and US Mortality Trends by Primary Cancer Site and Sex, Whites
I-9	SEER Incidence and US Mortality Trends by Primary Cancer Site and Sex, Blacks
I-10	Age Distribution of Incidence Cases by Site, 1998-2002
I-11	Median Age of Cancer Patients at Diagnosis, 1998-2002
I-12	Age Distribution of Deaths by Site, 1998-2002
I-13	Median Age of Cancer Patients at Death, 1998-2002
I-14	Lifetime Risk (By Site) of Being Diagnosed with Cancer - 13 SEER Areas
I-15	Lifetime Risk (By Site) of Dying from Cancer - Total US
I-16	US Death Rates Compared to SEER Death Rates by Primary Cancer Site and Race/Ethnicity
I-17	US Prevalance Counts by Site and Sex, January 1, 2002
I-18	US Prevalance Counts by Age at Prevalance, January 1, 2002
I-19	Top 15 Cancer Sites by Race/Ethnicity, Incidence, Both Sexes
I-20	Top 15 Cancer Sites by Race/Ethnicity, Incidence, Males
I-21	Top 15 Cancer Sites by Race/Ethnicity, Incidence, Females
I-22	Top 15 Cancer Sites by Race/Ethnicity, Mortality, Both Sexes
I-23	Top 15 Cancer Sites by Race/Ethnicity, Mortality, Males
I-24	Top 15 Cancer Sites by Race/Ethnicity, Mortality, Females

Chapter I
 Overview
 Chapter Contents - continued

Figure Number	Contents
I-1	Map of SEER Geographic Areas
I-2	Leading Causes of Death in US, 1975 vs 2002
I-3	US Death Rates, Heart Disease vs Neoplasms
I-4	Trends in SEER Incidence and US Death Rates by Primary Cancer Site
I-5	Trends in SEER Incidence Rates by Primary Cancer Site, Ages <65 and 65+
I-6	Trends in US Death Rates by Primary Cancer Site, Ages <65 and 65+
I-7	Trends in SEER Incidence Rates by Primary Cancer Site and Sex
I-8	Trends in US Death Rates by Primary Cancer Site and Sex
I-9	SEER Incidence and US Death Rates, 5 Year Relative Survival Rates by Race and Sex
I-10	Trends in US Death Rates by Primary Cancer Site and Race
I-11	5-Year Relative Survival Rates by Race
I-12	SEER Cancer Incidence and US Death Rates by Cancer Site and Race/Ethnicity
I-13	SEER Incidence, Top 3 Male Sites by Race/Ethnicity
I-14	SEER Incidence, Top 3 Female Sites by Race/Ethnicity
I-15	US Mortality, Top 3 Male Sites by Race/Ethnicity
I-16	US Mortality, Top 3 Female Sites by Race/Ethnicity
I-17	Incidence Percent Change 1992-2002, Burden vs Risk by Cancer Site
I-18	Mortality Percent Change 1992-2002, Burden vs Risk by Cancer Site
I-19	Person and Average Years of Life Lost to Cancer (2002)
I-20	Person and Average Years of Life Lost to Major Causes of Death (2002)
I-21	SEER Incidence and Delay Adjusted Incidence Rates by Sex, All Sites
I-22	SEER Incidence and Delay Adjusted Incidence Rates, Both Sexes, Lung and Bronchus, Colon and Rectum
I-23	SEER Incidence and Delay Adjusted Incidence Rates, Top 3 Male Sites
I-24	SEER Incidence and Delay Adjusted Incidence Rates, Top 3 Female Sites
I-25	Partition of SEER Incidence Trends, All Races, Both Sexes
I-26	Partition of SEER Incidence Trends, All Races, Males
I-27	Partition of SEER Incidence Trends, All Races, Females
I-28	Partition of US Mortality Trends, All Races, Both Sexes
I-29	Partition of US Mortality Trends, All Races, Males
I-30	Partition of US Mortality Trends, All Races, Females

Table I-1

ESTIMATED NEW CANCER CASES AND DEATHS FOR 2005

All Races, By Sex

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Males	Females	Total	Males	Females
All Sites	1,372,910	710,040	662,870	570,280	295,280	275,000
Oral Cavity and Pharynx	29,370	19,100	10,270	7,320	4,910	2,410
Tongue	7,660	5,050	2,610	1,730	1,120	610
Mouth	10,070	5,370	4,700	1,890	1,100	790
Pharynx	8,590	6,520	2,070	2,130	1,490	640
Other Oral Cavity	3,050	2,160	890	1,570	1,200	370
Digestive System	253,500	134,370	119,130	136,060	75,020	61,040
Esophagus	14,520	11,220	3,300	13,570	10,530	3,040
Stomach	21,860	13,510	8,350	11,550	6,770	4,780
Small Intestine	5,420	2,840	2,580	1,070	580	490
Colon	104,950	48,290	56,660			
Rectum ^a	40,340	23,530	16,810	56,290 ^a	28,540 ^a	27,750 ^a
Anus, Anal Canal, and Anorectum	3,990	1,750	2,240	620	230	390
Liver and Intrahepatic Bile Duct	17,550	12,130	5,420	15,420	10,330	5,090
Gallbladder and Other Biliary	7,480	3,330	4,150	3,340	1,270	2,070
Pancreas	32,180	16,100	16,080	31,800	15,820	15,980
Other Digestive	5,210	1,670	3,540	2,400	950	1,450
Respiratory System	184,800	102,420	82,380	168,140	93,990	74,150
Larynx	9,880	7,920	1,960	3,770	2,960	810
Lung and Bronchus	172,570	93,010	79,560	163,510	90,490	73,020
Other Respiratory	2,350	1,490	860	860	540	320
Bones and Joints	2,570	1,480	1,090	1,210	670	540
Soft Tissue	9,420	5,530	3,890	3,490	1,910	1,580
Skin (excl. basal & squamous)	66,000	37,580	28,420	10,590	6,920	3,670
Melanoma of the Skin ^b	59,580	33,580	26,000	7,770	4,910	2,860
Other non-epithelial skin	6,420	4,000	2,420	2,820	2,010	810
Breast ^b	212,930	1,690	211,240	40,870	460	40,410
Genital Organs	321,050	241,570	79,480	59,920	31,010	28,910
Cervix (uterus)	10,370		10,370	3,710		3,710
Endometrium (uterus)	40,880		40,880	7,310		7,310
Ovary	22,220		22,220	16,210		16,210
Vulva	3,870		3,870	870		870
Vagina and other genital organs, female	2,140		2,140	810		810
Prostate	232,090	232,090		30,350	30,350	
Testis	8,010	8,010		390	390	
Penis and other genital organs, male	1,470	1,470		270	270	
Urinary System	101,880	71,090	30,790	26,590	17,420	9,170
Urinary Bladder	63,210	47,010	16,200	13,180	8,970	4,210
Kidney and Renal Pelvis	36,160	22,490	13,670	12,660	8,020	4,640
Ureter and other urinary organs	2,510	1,590	920	750	430	320
Eye and Orbit	2,120	1,090	1,030	230	110	120
Brain and Other Nervous System	18,500	10,620	7,880	12,760	7,280	5,480
Endocrine System	27,650	7,550	20,100	2,370	1,080	1,290
Thyroid	25,690	6,500	19,190	1,490	630	860
Other Endocrine	1,960	1,050	910	880	450	430
Lymphoma	63,740	33,050	30,690	20,610	10,930	9,680
Hodgkin Lymphoma	7,350	3,980	3,370	1,410	780	630
Non-Hodgkin Lymphoma	56,390	29,070	27,320	19,200	10,150	9,050
Myeloma	15,980	8,600	7,380	11,300	5,660	5,640
Leukemia	34,810	19,640	15,170	22,570	12,540	10,030
Lymphocytic Leukemias	13,700	7,960	5,740	6,090	3,370	2,720
Myeloid Leukemias	16,560	9,170	7,390	9,850	5,470	4,380
Other leukemia	4,550	2,510	2,040	6,630	3,700	2,930
All Other Sites ^c	28,590	14,660	13,930	46,250	25,370	20,880

Cancer Facts & Figures - 2005, American Cancer Society (ACS), Atlanta, Georgia, 2005.
Excludes basal and squamous cell skin and *in situ* carcinomas except urinary bladder.
Incidence projections are based on rates from the NCI SEER Program 1979-2001.

^a

Estimated deaths for colon & rectum cancers are combined.

^b

Carcinoma *in situ* of the breast accounts for about 58,490 new cases annually, and melanoma *in situ* accounts for about 46,170 new cases annually.

^c

More deaths than cases suggests lack of specificity in recording underlying causes of death on death certificate.

Table I-2

53-YEAR TRENDS IN U.S. CANCER DEATH RATES^a

All Races, Males and Females

All Primary Cancer Sites Combined

Age Group	1950	1976	2002	Annual Percent Change		Total Percent Change
				1950-1976	1976-2002	1950-2002
0-4	11.1	4.8	2.4	-2.9	-2.8	-78.1
5-14	6.7	4.9	2.6	-1.1	-2.7	-60.7
15-24	8.6	6.4	4.2	-0.8	-1.6	-50.7
25-34	20.4	14.8	9.7	-1.3	-1.4	-52.3
35-44	63.6	52.0	35.7	-0.5	-1.4	-43.9
45-54	174.2	177.8	123.7	0.1	-1.5	-29.0
55-64	391.3	426.8	352.9	0.3	-0.7	-9.8
65-74	710.0	785.1	792.7	0.4	0.1	11.6
75-84	1,167.2	1,192.7	1,306.1	0.1	0.4	11.9
85+	1,450.7	1,506.7	1,732.5	-0.1	0.7	19.4
All Ages	195.4	202.3	193.5	0.1	-0.1	-1.0

Lung and Bronchus Cancer^b

Age Group	1950	1976	2002	Annual Percent Change		Total Percent Change
				1950-1976	1976-2002	1950-2002
0-4	-	-	-	-	-	-
5-14	-	-	-	-	-	-
15-24	0.2	0.1	-	-2.4	-1.0	-67.4
25-34	0.8	0.8	0.4	0.3	-1.8	-48.8
35-44	4.6	10.3	6.0	3.5	-2.3	30.6
45-54	20.2	49.9	30.3	3.6	-2.3	49.8
55-64	48.9	126.0	116.2	3.5	-0.4	137.8
65-74	59.4	202.2	275.7	4.4	1.1	363.9
75-84	55.4	206.5	378.0	5.2	2.2	582.6
85+	42.3	147.7	299.4	5.2	2.8	608.0
All Ages	14.9	44.4	55.1	4.2	0.7	268.5

Source: NCHS public use data file for the total US.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are per 100,000 and age-adjusted to the 2000 US Std Population (18 age groups - Census P25-1130).^b Due to coding changes throughout the years, Lung and Bronchus includes trachea and pleura.

Table I-3

SUMMARY OF CHANGES IN CANCER INCIDENCE AND MORTALITY, 1950-2002 AND
5-YEAR RELATIVE SURVIVAL RATES, 1950-2001

Males and Females, By Primary Cancer Site

Table is temporarily unavailable and will be added soon.

Table I-4
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Incidence ^a (1998-2002)			US Mortality ^b (1998-2002)			Survival ^c (1995-2001)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
	All Races								
All Sites	469.7	553.3	413.5	197.8	247.5	165.5	65.0	65.0	65.0
Oral Cavity & Pharynx:	10.5	15.5	6.4	2.8	4.2	1.6	59.4	58.0	62.3
Lip	0.9	1.6	0.4	0.0	0.0	0.0	92.4	93.1	88.3
Tongue	2.6	3.8	1.6	0.6	0.9	0.4	56.2	55.8	56.7
Salivary gland	1.2	1.6	0.9	0.2	0.4	0.2	75.4	69.9	80.4
Floor of mouth	0.8	1.1	0.5	0.1	0.1	0.0	52.9	50.8	57.1
Gum & other oral cavity	1.6	1.9	1.4	0.4	0.6	0.3	60.0	54.7	66.2
Nasopharynx	0.7	1.0	0.4	0.2	0.3	0.1	58.0	58.1	57.5
Tonsil	1.3	2.2	0.5	0.2	0.3	0.1	58.4	58.4	58.2
Oropharynx	0.3	0.5	0.2	0.2	0.3	0.1	38.9	37.6	42.2
Hypopharynx	0.8	1.4	0.3	0.1	0.2	0.1	30.5	31.3	26.4
Other oral cavity & pharynx	0.3	0.4	0.1	0.6	1.0	0.3	30.7	30.6	31.1
Digestive System:	90.9	111.2	75.2	47.0	60.3	37.0	45.1	43.5	46.9
Esophagus	4.5	7.7	2.0	4.4	7.7	1.8	14.9	14.8	15.1
Stomach	8.8	12.3	6.1	4.5	6.3	3.2	23.2	22.2	24.9
Small intestine	1.7	2.1	1.5	0.4	0.5	0.3	54.5	53.6	55.2
Colon & Rectum:	52.9	62.1	46.0	20.5	24.8	17.4	64.1	64.7	63.5
Colon	38.3	43.4	34.5	-	-	-	63.9	65.1	62.9
Rectum	14.6	18.7	11.5	-	-	-	64.7	64.1	65.4
Anus, anal canal & anorectum	1.4	1.3	1.5	0.2	0.2	0.2	67.8	60.8	72.9
Liver & Intrahep:	6.2	9.3	3.6	4.7	6.8	3.0	9.0	8.4	10.1
Liver	5.4	8.3	2.9	3.7	5.7	2.1	9.7	8.8	11.8
Intrahep bile duct	0.8	1.0	0.6	1.0	1.1	0.9	4.8	5.3	4.2
Gallbladder	1.2	0.8	1.6	0.7	0.5	0.9	15.4	15.5	15.1
Other biliary	1.6	1.9	1.3	0.6	0.7	0.5	21.0	23.5	18.1
Pancreas	11.0	12.5	9.8	10.5	12.2	9.2	4.6	4.5	4.7
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	51.0	49.0	52.8
Peritoneum, omentum & mesentery	0.6	0.1	1.0	0.2	0.1	0.3	35.4	41.1	34.8
Other digestive system	0.5	0.6	0.5	0.3	0.4	0.3	9.1	5.3	12.1
Respiratory System:	65.5	85.4	51.0	57.4	79.4	41.7	19.0	18.8	19.3
Nose, nasal cavity & middle ear	0.7	0.8	0.5	0.2	0.2	0.1	54.2	52.1	56.4
Larynx	3.6	6.5	1.4	1.4	2.5	0.5	65.6	67.3	59.3
Lung & bronchus	61.0	77.8	48.9	55.7	76.3	40.9	15.3	13.6	17.5
Pleura ^d	0.0	0.1	-	0.1	0.2	0.0	21.3	20.7	-
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	44.6	43.7	45.6
Bones & joints	0.9	1.0	0.7	0.4	0.5	0.4	69.4	67.6	71.6
Soft tissue (incl heart)	2.9	3.5	2.4	1.3	1.5	1.2	67.2	67.5	66.8
Skin (ex basal & squam):	19.0	24.2	15.4	3.5	5.3	2.2	91.4	89.9	93.0
Melanoma of the skin	17.2	21.8	14.0	2.7	3.9	1.8	91.6	90.2	93.3
Other non-epithelial skin	1.8	2.4	1.4	0.8	1.4	0.4	88.7	87.1	90.4
Breast	73.3	1.2	134.4	15.0	0.3	26.4	88.2	84.6	88.2
Breast (<i>in situ</i>)	16.6	0.1	31.0	-	-	-	100.0	99.5	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

^b NCHS public use data file for the total US.

^c SEER 9 areas.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-4 - continued
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	All Races								
	Incidence ^a (1998-2002)			US Mortality ^b (1998-2002)			Survival ^c (1995-2001)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.5	-	50.7	9.5	-	16.7	70.7	-	70.7
Cervix uteri	4.7	-	8.9	1.5	-	2.8	73.3	-	73.3
Corpus uteri	12.9	-	23.8	1.1	-	2.0	85.3	-	85.3
Uterus, NOS	0.3	-	0.5	1.2	-	2.2	30.6	-	30.6
Ovary	7.6	-	13.9	5.0	-	8.9	44.6	-	44.6
Vagina	0.4	-	0.7	0.1	-	0.2	44.5	-	44.5
Vulva	1.3	-	2.2	0.3	-	0.5	78.1	-	78.1
Other female genital system	0.4	-	0.7	0.1	-	0.2	61.2	-	61.2
Male Genital System:	79.1	180.2	-	11.5	30.8	-	99.5	99.5	-
Prostate	76.0	173.8	-	11.2	30.3	-	99.8	99.8	-
Testis	2.6	5.3	-	0.1	0.3	-	96.0	96.0	-
Penis	0.3	0.8	-	0.1	0.2	-	74.5	74.5	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	75.4	75.4	-
Urinary System:	32.8	53.4	17.6	8.8	14.0	5.2	74.9	76.8	70.9
Urinary bladder	20.3	36.0	9.1	4.4	7.6	2.3	81.8	83.5	77.3
Kidney & renal pelvis	11.6	16.2	8.0	4.2	6.1	2.8	64.6	64.3	65.0
Ureter	0.5	0.8	0.3	0.1	0.2	0.1	53.2	53.9	51.5
Other urinary system	0.3	0.5	0.2	0.1	0.1	0.1	57.3	69.3	36.5
Eye & Orbit	0.8	0.9	0.6	0.1	0.1	0.1	81.3	84.7	77.6
Brain & Nervous System: ^d	6.4	7.6	5.3	4.5	5.6	3.7	33.3	32.4	34.4
Brain	6.0	7.2	4.9	-	-	-	30.4	29.6	31.4
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	75.9	77.7	73.6
Endocrine System:	8.3	4.8	11.7	0.8	0.8	0.8	93.6	88.3	95.4
Thyroid	7.6	4.0	11.1	0.5	0.4	0.5	96.6	93.9	97.4
Other endocrine & thymus	0.7	0.8	0.6	0.3	0.4	0.3	60.3	61.3	59.1
Lymphoma:	21.8	26.3	18.2	8.6	10.8	7.0	64.2	62.3	66.6
Hodgkin lymphoma	2.7	3.0	2.4	0.5	0.6	0.4	85.3	83.8	87.0
Non-Hodgkin lymphoma	19.1	23.2	15.8	8.1	10.2	6.6	60.2	58.2	62.6
Myeloma	5.5	6.9	4.5	3.8	4.7	3.2	32.4	36.1	28.4
Leukemia:	12.2	15.9	9.4	7.6	10.2	5.8	47.6	48.3	46.7
Lymphocytic:	5.6	7.5	4.0	2.2	3.1	1.6	71.4	71.2	71.7
Acute lymphocytic	1.5	1.7	1.4	0.5	0.6	0.4	64.6	64.1	65.3
Chronic lymphocytic	3.6	5.1	2.4	1.6	2.3	1.1	74.2	73.0	76.0
Other lymphocytic	0.4	0.7	0.2	0.1	0.2	0.1	78.7	82.5	68.8
Myeloid & Monocytic:	5.8	7.3	4.7	3.5	4.6	2.8	25.6	25.1	26.2
Acute myeloid	3.8	4.7	3.1	2.6	3.4	2.1	19.8	18.8	20.9
Chronic myeloid	1.6	2.1	1.2	0.6	0.8	0.5	39.0	38.3	40.1
Acute monocytic	0.3	0.4	0.2	0.0	0.1	0.0	16.7	17.2	16.5
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.1	25.9	26.0	23.2
Other:	0.8	1.0	0.6	1.9	2.5	1.5	16.6	16.8	16.3
Other acute	0.4	0.5	0.3	0.9	1.2	0.7	7.6	6.4	8.8
Aleukemic, subleuk & NOS	0.4	0.5	0.3	1.0	1.3	0.8	28.4	31.1	25.8
Kaposi Sarcoma ^e	0.9	1.7	0.1	-	-	-	45.2	44.8	52.7
Mesothelioma ^e	1.0	1.9	0.4	-	-	-	9.0	6.6	17.2
Ill-defined & unspecified	10.5	11.8	9.5	15.2	19.1	12.5	15.2	18.1	12.7

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- ^a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
- ^b NCHS public use data file for the total US.
- ^c SEER 9 areas.
- ^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- ^e Rate not shown for mortality. Category did not exist in mortality coding until 1999.
- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-5
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Whites			Whites			Whites		
	Incidence ^a (1998-2002)			US Mortality ^b (1998-2002)			Survival ^c (1995-2001)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	479.7	556.4	429.3	195.3	242.5	164.5	66.4	66.5	66.3
Oral Cavity & Pharynx:	10.5	15.4	6.4	2.6	3.9	1.6	61.8	61.1	63.1
Lip	1.1	1.9	0.4	0.0	0.1	0.0	92.8	93.1	90.2
Tongue	2.7	3.9	1.7	0.6	0.9	0.4	58.3	58.4	57.6
Salivary gland	1.2	1.7	1.0	0.3	0.4	0.2	75.0	69.8	79.4
Floor of mouth	0.8	1.2	0.5	0.1	0.1	0.0	54.8	54.1	56.2
Gum & other oral cavity	1.7	1.9	1.4	0.4	0.5	0.3	61.9	58.0	66.0
Nasopharynx	0.4	0.5	0.2	0.2	0.3	0.1	54.4	52.3	57.5
Tonsil	1.4	2.2	0.6	0.2	0.3	0.1	61.8	62.6	59.0
Oropharynx	0.3	0.4	0.2	0.2	0.3	0.1	40.5	38.8	44.8
Hypopharynx	0.8	1.3	0.3	0.1	0.2	0.1	32.7	33.6	28.4
Other oral cavity & pharynx	0.3	0.4	0.2	0.5	0.9	0.2	33.3	33.5	32.6
Digestive System:	87.7	107.1	72.6	45.2	58.0	35.4	46.6	45.1	48.3
Esophagus	4.5	7.8	1.9	4.2	7.5	1.7	16.2	16.1	16.4
Stomach	7.4	10.7	5.0	4.0	5.6	2.8	21.4	19.9	23.9
Small intestine	1.7	2.0	1.4	0.4	0.5	0.3	56.3	55.4	56.9
Colon & Rectum:	52.5	61.7	45.3	20.0	24.3	16.8	65.0	65.6	64.4
Colon	37.9	43.1	34.0	-	-	-	64.9	66.1	63.9
Rectum	14.6	18.6	11.4	-	-	-	65.1	64.5	65.9
Anus, anal canal & anorectum	1.5	1.3	1.6	0.2	0.2	0.2	69.4	63.0	73.9
Liver & Intrahep:	5.0	7.4	2.9	4.3	6.2	2.7	8.5	7.4	10.6
Liver	4.2	6.4	2.3	3.3	5.1	1.9	9.4	7.9	13.2
Intrahep bile duct	0.8	1.0	0.6	1.0	1.1	0.9	4.4	4.7	4.1
Gallbladder	1.2	0.8	1.5	0.7	0.5	0.8	14.4	14.9	14.0
Other biliary	1.5	1.9	1.3	0.6	0.7	0.5	21.0	24.3	16.9
Pancreas	10.9	12.5	9.5	10.3	12.0	9.0	4.4	4.7	4.2
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	54.4	52.0	56.7
Peritoneum, omentum & mesentery	0.7	0.1	1.1	0.2	0.1	0.3	34.2	34.6	34.1
Other digestive system	0.5	0.6	0.4	0.3	0.4	0.2	10.0	5.6	13.7
Respiratory System:	66.3	84.2	53.2	57.4	78.1	42.6	19.3	19.2	19.4
Nose, nasal cavity & middle ear	0.7	0.8	0.5	0.2	0.2	0.1	57.0	56.0	57.5
Larynx	3.6	6.4	1.4	1.3	2.3	0.5	67.9	69.5	61.9
Lung & bronchus	61.7	76.7	51.1	55.8	75.2	41.8	15.5	13.7	17.7
Pleura ^d	0.0	0.1	-	0.1	0.2	0.0	15.9	-	-
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	47.7	47.4	45.9
Bones & joints	0.9	1.0	0.8	0.4	0.6	0.4	69.6	67.5	72.1
Soft tissue (incl heart)	2.9	3.6	2.4	1.3	1.5	1.2	68.1	68.7	67.4
Skin (ex basal & squam):	22.7	28.5	18.6	3.9	5.8	2.4	91.5	90.0	93.2
Melanoma of the skin	20.8	25.9	17.2	3.0	4.3	2.0	91.8	90.3	93.5
Other non-epithelial skin	1.9	2.6	1.5	0.9	1.5	0.5	87.6	86.1	89.3
Breast	76.3	1.2	141.1	14.7	0.3	25.9	89.5	88.6	89.5
Breast (<i>in situ</i>)	16.9	0.2	31.9	-	-	-	100.0	98.6	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

^b NCHS public use data file for the total US.

^c SEER 9 areas.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-5 - continued
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence ^a (1998-2002)			US Mortality ^b (1998-2002)			Survival ^c (1995-2001)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	28.5	-	53.1	9.3	-	16.5	71.8	-	71.8
Cervix uteri	4.5	-	8.7	1.3	-	2.5	74.6	-	74.6
Corpus uteri	13.6	-	25.3	1.1	-	1.9	87.0	-	87.0
Uterus, NOS	0.2	-	0.4	1.1	-	2.0	31.6	-	31.6
Ovary	8.0	-	14.8	5.2	-	9.2	44.4	-	44.4
Vagina	0.4	-	0.7	0.1	-	0.2	43.7	-	43.7
Vulva	1.4	-	2.4	0.3	-	0.5	78.3	-	78.3
Other female genital system	0.4	-	0.8	0.1	-	0.2	59.9	-	59.9
Male Genital System:	78.2	176.4	-	10.5	28.2	-	99.8	99.8	-
Prostate	74.5	169.0	-	10.3	27.7	-	99.9	99.9	-
Testis	3.2	6.3	-	0.1	0.3	-	96.3	96.3	-
Penis	0.3	0.8	-	0.1	0.2	-	73.3	73.3	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	80.1	80.1	-
Urinary System:	35.3	57.8	18.6	9.0	14.4	5.2	76.1	77.9	71.9
Urinary bladder	22.5	39.7	9.9	4.5	7.9	2.3	82.8	84.3	78.6
Kidney & renal pelvis	12.0	16.7	8.3	4.3	6.2	2.8	64.7	64.7	64.5
Ureter	0.5	0.8	0.3	0.1	0.2	0.1	56.1	56.4	55.2
Other urinary system	0.3	0.5	0.1	0.1	0.1	0.1	60.9	69.9	41.4
Eye & Orbit	0.9	1.0	0.8	0.1	0.1	0.1	81.1	84.5	77.5
Brain & Nervous System: ^d	7.1	8.4	6.0	4.9	5.9	4.0	32.7	32.1	33.5
Brain	6.7	8.1	5.6	-	-	-	29.7	29.1	30.4
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	78.7	81.3	75.4
Endocrine System:	8.6	5.0	12.2	0.8	0.8	0.7	94.0	89.0	95.8
Thyroid	7.9	4.2	11.7	0.5	0.5	0.5	96.9	94.4	97.7
Other endocrine & thymus	0.6	0.8	0.5	0.3	0.4	0.3	59.4	59.3	59.1
Lymphoma:	23.1	27.6	19.4	9.0	11.2	7.3	65.2	63.5	67.2
Hodgkin lymphoma	2.9	3.3	2.6	0.5	0.6	0.4	86.0	84.6	87.7
Non-Hodgkin lymphoma	20.2	24.4	16.7	8.5	10.6	6.9	61.2	59.5	63.3
Myeloma	5.2	6.7	4.1	3.5	4.4	2.9	32.2	35.8	28.1
Leukemia:	12.9	16.9	9.9	7.8	10.4	6.0	49.1	49.6	48.4
Lymphocytic:	6.1	8.2	4.4	2.3	3.2	1.6	73.0	72.8	73.2
Acute lymphocytic	1.7	1.9	1.5	0.5	0.6	0.4	65.9	65.2	66.7
Chronic lymphocytic	3.9	5.6	2.6	1.6	2.4	1.1	75.5	74.3	77.1
Other lymphocytic	0.5	0.8	0.3	0.1	0.2	0.1	80.6	84.5	70.4
Myeloid & Monocytic:	6.0	7.6	4.9	3.6	4.7	2.8	25.2	24.3	26.4
Acute myeloid	3.9	4.9	3.3	2.7	3.5	2.2	19.2	17.9	20.6
Chronic myeloid	1.6	2.1	1.3	0.6	0.8	0.5	39.0	37.6	41.2
Acute monocytic	0.3	0.4	0.2	0.0	0.1	0.0	18.2	19.4	16.4
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.1	28.2	26.1	27.9
Other:	0.8	1.1	0.7	1.9	2.5	1.5	16.6	16.5	16.7
Other acute	0.4	0.5	0.3	0.9	1.2	0.7	6.7	4.3	9.0
Aleukemic, subleuk & NOS	0.4	0.5	0.3	1.0	1.3	0.8	30.2	33.5	25.3
Kaposi Sarcoma ^e	0.8	1.5	0.1	-	-	-	49.1	48.3	65.2
Mesothelioma ^e	1.1	2.1	0.4	-	-	-	9.0	6.5	17.7
Ill-defined & unspecified	10.5	11.8	9.5	15.0	18.8	12.3	15.9	19.2	13.1

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

^b NCHS public use data file for the total US.

^c SEER 9 areas.

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^e Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-6
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Incidence ^a (1998-2002)			US Mortality ^b (1998-2002)			Survival ^c (1995-2001)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
	All Sites	512.3	682.6	398.5	248.1	339.4	194.3	56.0	58.4
Oral Cavity & Pharynx:	11.6	19.0	6.1	4.1	7.1	1.9	39.5	34.3	52.0
Lip	0.2	-	-	-	-	-	-	-	-
Tongue	2.7	4.3	1.4	0.8	1.4	0.4	37.0	34.7	42.6
Salivary gland	0.9	1.1	0.8	0.2	0.2	0.2	74.9	64.9	85.4
Floor of mouth	1.1	1.9	0.4	0.1	0.2	0.0	40.0	29.3	62.4
Gum & other	1.9	2.8	1.3	0.6	0.9	0.3	46.4	36.2	64.8
oral cavity									
Nasopharynx	0.6	0.9	0.4	0.3	0.5	0.2	41.0	47.1	20.6
Tonsil	1.8	3.3	0.7	0.4	0.7	0.1	35.2	31.8	47.7
Oropharynx	0.6	1.1	-	0.4	0.8	0.2	30.4	32.5	-
Hypopharynx	1.4	2.6	0.4	0.2	0.4	0.1	16.0	17.3	11.5
Other oral cavity & pharynx	0.4	0.8	-	1.1	2.1	0.4	18.2	17.8	-
Digestive System:	112.8	138.2	95.1	66.1	86.1	52.6	36.5	33.8	39.2
Esophagus	6.5	10.4	3.6	6.5	11.2	3.2	9.6	8.6	11.6
Stomach	12.9	17.7	9.6	8.8	12.8	6.3	22.8	21.5	24.2
Small intestine	3.2	4.0	2.7	0.6	0.7	0.5	48.1	44.6	50.9
Colon & Rectum:	62.4	72.5	56.0	27.9	34.0	24.1	55.0	55.9	54.3
Colon	48.4	55.0	44.4	-	-	-	54.7	56.3	53.6
Rectum	14.0	17.4	11.6	-	-	-	56.0	55.0	57.0
Anus, anal canal & anorectum	1.6	1.8	1.4	0.2	0.2	0.2	57.1	51.8	61.9
Liver & Intrahep:	7.3	12.1	3.7	6.2	9.5	3.8	5.1	5.5	4.6
Liver	6.7	11.2	3.3	5.3	8.5	3.0	5.1	5.4	4.3
Intrahep bile duct	0.6	0.8	0.4	0.9	1.0	0.8	0.0	0.0	-
Gallbladder	1.2	0.7	1.5	0.8	0.5	1.0	15.1	10.7	15.8
Other biliary	1.4	1.9	1.1	0.5	0.5	0.4	22.1	14.4	27.6
Pancreas	14.9	16.3	13.6	14.0	15.8	12.6	4.4	2.9	5.6
Retroperitoneum	0.4	0.4	0.5	0.1	0.1	0.1	42.3	47.6	38.3
Peritoneum, omentum & mesentery	0.4	-	0.6	0.1	0.1	0.2	35.1	-	33.4
Other digestive system	0.7	0.6	0.7	0.4	0.6	0.4	0.0	-	0.0
Respiratory System:	86.0	126.7	58.2	67.0	107.0	41.0	16.6	16.0	17.7
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.2	0.3	0.1	35.2	26.3	47.6
Larynx	6.2	11.5	2.3	2.6	5.2	0.9	51.2	53.3	45.2
Lung & bronchus	78.8	113.9	55.2	64.1	101.3	39.9	13.2	11.6	15.6
Pleura ^d	-	-	-	0.1	0.1	-	-	-	-
Trachea & other respiratory organs	0.2	-	-	0.1	0.2	0.1	22.0	17.4	-
Bones & joints	0.7	0.8	0.6	0.4	0.6	0.3	69.7	70.0	68.4
Soft tissue (incl heart)	3.0	3.5	2.6	1.5	1.6	1.5	60.8	58.7	63.0
Skin (ex basal & squam):	2.2	2.6	1.9	1.1	1.6	0.7	88.6	85.8	88.8
Melanoma of the skin	1.0	1.3	0.8	0.4	0.5	0.4	77.5	75.7	78.2
Other non-epithelial skin	1.2	1.3	1.1	0.6	1.1	0.3	96.1	93.5	95.6
Breast	68.9	1.9	119.4	20.6	0.6	34.7	75.7	56.0	75.9
Breast (<i>in situ</i>)	15.5	-	27.3	-	-	-	100.0	-	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

^b NCHS public use data file for the total US.

^c SEER 9 areas.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-6 - continued
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
 By Primary Cancer Site, Sex and Time Period

Site	Blacks								
	Incidence ^a (1998-2002)			US Mortality ^b (1998-2002)			Survival ^c (1995-2001)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	25.1	-	43.6	12.4	-	20.7	58.2	-	58.2
Cervix uteri	6.3	-	11.1	3.1	-	5.3	66.1	-	66.1
Corpus uteri	10.5	-	18.2	1.9	-	3.1	63.2	-	63.2
Uterus, NOS	0.5	-	0.8	2.4	-	3.9	33.6	-	33.6
Ovary	5.8	-	9.9	4.4	-	7.4	37.7	-	37.7
Vagina	0.6	-	1.1	0.2	-	0.4	39.9	-	39.9
Vulva	1.0	-	1.7	0.2	-	0.3	70.1	-	70.1
Other female genital system	0.4	-	0.7	0.2	-	0.3	70.6	-	70.6
Male Genital System:	113.0	274.6	-	23.9	68.6	-	96.5	96.5	-
Prostate	111.8	272.0	-	23.8	68.1	-	96.7	96.7	-
Testis	0.7	1.5	-	0.1	0.2	-	87.8	87.8	-
Penis	0.3	0.9	-	0.1	0.2	-	66.7	66.7	-
Other male genital system	-	-	-	0.0	0.1	-	-	-	-
Urinary System:	27.1	40.7	18.0	8.2	11.9	5.9	63.3	65.1	60.5
Urinary bladder	12.6	20.1	7.7	3.9	5.5	2.9	64.3	69.7	53.9
Kidney & renal pelvis	13.7	19.4	9.7	4.1	6.2	2.7	63.6	61.8	65.9
Ureter	0.3	0.4	-	0.0	-	0.1	-	-	-
Other urinary system	0.5	0.7	0.4	0.2	0.2	0.2	47.8	66.2	0.0
Eye & Orbit	0.2	-	-	0.0	-	0.0	79.2	-	-
Brain & Nervous System: ^d	3.9	4.5	3.4	2.7	3.3	2.2	37.6	37.7	37.5
Brain	3.5	4.2	3.0	-	-	-	35.8	36.2	35.2
Cranial nerves & other nervous system	0.4	0.4	0.5	-	-	-	54.5	53.6	53.8
Endocrine System:	5.1	3.1	6.7	0.8	0.7	0.9	89.9	83.9	91.4
Thyroid	4.4	2.2	6.2	0.5	0.4	0.5	94.8	89.2	95.4
Other endocrine & thymus	0.7	0.8	0.6	0.4	0.4	0.3	58.6	68.3	49.0
Lymphoma:	16.7	20.6	13.7	6.0	7.7	4.8	58.2	53.5	64.6
Hodgkin lymphoma	2.5	3.0	2.0	0.4	0.5	0.3	80.4	77.8	83.3
Non-Hodgkin lymphoma	14.2	17.6	11.6	5.6	7.1	4.5	52.3	47.6	59.1
Myeloma	11.0	13.1	9.5	7.4	8.8	6.5	33.3	36.3	30.5
Leukemia:	9.7	12.4	7.8	6.8	8.9	5.4	38.1	39.2	36.9
Lymphocytic:	3.8	5.1	2.9	2.0	2.8	1.4	56.1	54.7	58.1
Acute lymphocytic	0.8	0.8	0.7	0.4	0.5	0.3	54.4	54.2	54.8
Chronic lymphocytic	2.8	3.9	2.0	1.5	2.2	1.0	57.5	53.8	62.2
Other lymphocytic	0.3	0.4	-	0.1	0.2	0.1	49.7	-	-
Myeloid & Monocytic:	5.1	6.3	4.2	3.0	3.8	2.5	26.4	28.6	24.1
Acute myeloid	3.3	4.1	2.8	2.1	2.6	1.8	22.2	25.5	19.2
Chronic myeloid	1.4	1.9	1.0	0.7	0.9	0.6	34.8	33.9	35.3
Acute monocytic	-	-	-	0.0	-	-	-	-	-
Other myeloid & monocytic	0.2	-	-	0.1	0.2	0.1	-	-	-
Other:	0.7	0.9	0.6	1.8	2.3	1.5	17.1	12.8	20.7
Other acute	0.4	0.5	-	0.7	0.9	0.6	13.0	10.4	-
Aleukemic, subleuk & NOS	0.4	0.4	0.4	1.1	1.5	0.9	22.2	-	-
Kaposi Sarcoma ^e	1.8	3.7	-	-	-	-	34.0	34.1	34.5
Mesothelioma ^e	0.6	1.1	-	-	-	-	14.7	10.0	-
Ill-defined & unspecified	13.3	15.8	11.5	19.1	24.9	15.2	10.5	11.9	8.9

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- ^a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
- ^b NCHS public use data file for the total US.
- ^c SEER 9 areas.
- ^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- ^e Rate not shown for mortality. Category did not exist in mortality coding until 1999.
- Statistic could not be calculated due to less than 25 cases in the time interval.

Table I-7
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
All Races, 1992-2002

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-0.6 ^c	-1.3 ^c	0.1	-1.0 ^c	-1.5 ^c	-0.7 ^c
Oral Cavity & Pharynx:	-1.5 ^c	-1.8 ^c	-1.1 ^c	-2.5 ^c	-2.7 ^c	-2.4 ^c
Lip	-4.7 ^c	-5.9 ^c	-1.3	-4.8 ^c	-5.3 ^c	-5.1 ^c
Tongue	0.7	0.4	0.8	-1.6 ^c	-2.0 ^c	-1.2 ^c
Salivary gland	0.4	0.2	0.7	-1.4 ^c	-1.6 ^c	-1.5 ^c
Floor of mouth	-4.4 ^c	-4.4 ^c	-4.4 ^c	-9.1 ^c	-8.9 ^c	-9.4 ^c
Gum & other oral cavity	-2.4 ^c	-2.7 ^c	-2.2 ^c	-3.9 ^c	-4.5 ^c	-3.4 ^c
Nasopharynx	-1.4 ^c	-2.0 ^c	-0.3	-2.8 ^c	-3.2 ^c	-2.0 ^c
Tonsil	1.3 ^c	2.3 ^c	-2.3 ^c	-1.0	-0.9	-1.9 ^c
Oropharynx	-1.8	-2.7	0.3	-0.4	-0.5	-0.5
Hypopharynx	-3.6 ^c	-3.9 ^c	-3.1 ^c	-5.2 ^c	-5.7 ^c	-4.0 ^c
Other oral cavity & pharynx	-5.6 ^c	-6.2 ^c	-5.2 ^c	-2.0 ^c	-1.8 ^c	-2.9 ^c
Digestive System:	-0.3	-0.7 ^c	-0.2	-1.0 ^c	-1.1 ^c	-1.1 ^c
Esophagus	0.0	0.3	-1.0 ^c	0.6 ^c	0.6 ^c	-0.2
Stomach	-1.5 ^c	-2.1 ^c	-0.7	-3.0 ^c	-3.4 ^c	-2.6 ^c
Small intestine	1.9 ^c	1.5	2.4 ^c	-1.3 ^c	-1.2	-1.5 ^c
Colon & Rectum:	-0.8 ^c	-1.2 ^c	-0.6 ^c	-1.8 ^c	-2.0 ^c	-1.8 ^c
Colon	-0.9 ^c	-1.3 ^c	-0.6 ^c	-	-	-
Rectum	-0.6	-0.9 ^c	-0.5	-	-	-
Anus, anal canal & anorectum	1.9 ^c	1.9 ^c	2.0 ^c	1.3 ^c	1.2	1.5 ^c
Liver & Intrahep:	3.3 ^c	3.0 ^c	3.3 ^c	1.9 ^c	2.1 ^c	1.2 ^c
Liver	4.2 ^c	3.7 ^c	4.6 ^c	1.5 ^c	1.8 ^c	0.2
Intrahep bile duct	-1.3	-1.7	-1.2	3.7 ^c	3.2 ^c	4.0 ^c
Gallbladder	-1.7 ^c	-1.5	-1.5 ^c	-2.5 ^c	-2.0 ^c	-2.5 ^c
Other biliary	0.6	0.7	0.4	-3.1 ^c	-3.2 ^c	-3.1 ^c
Pancreas	-0.3	-0.4 ^c	-0.3	-0.1	-0.3 ^c	-0.1
Retroperitoneum	-0.6	0.9	-1.7 ^c	-3.7 ^c	-3.7 ^c	-3.7 ^c
Peritoneum, omentum & mesentery	9.2 ^c	-1.6	10.4 ^c	7.6 ^c	-0.8	10.2 ^c
Other digestive system	5.0 ^c	3.2 ^c	6.3 ^c	8.1 ^c	8.4 ^c	7.7 ^c
Respiratory System:	-1.4 ^c	-2.3 ^c	-0.3	-0.9 ^c	-1.9 ^c	0.5 ^c
Nose, nasal cavity & middle ear	-1.3	-1.8	-1.1	-2.3 ^c	-2.3 ^c	-3.0 ^c
Larynx	-3.0 ^c	-3.3 ^c	-2.4 ^c	-2.1 ^c	-2.5 ^c	-1.7 ^c
Lung & bronchus	-1.3 ^c	-2.2 ^c	-0.2	-0.8 ^c	-1.9 ^c	0.6 ^c
Pleura	2.1	1.5	-	-6.0 ^c	-6.2 ^c	-5.8 ^c
Trachea & other respiratory organs	-3.6 ^c	-4.0 ^c	-3.2	-3.9 ^c	-4.1 ^c	-3.9 ^c
Bones & joints	-0.6	-0.7	-0.5	-1.0 ^c	-1.3 ^c	-1.1 ^c
Soft tissue (incl heart)	1.2 ^c	1.8 ^c	0.6	-1.7 ^c	-1.3 ^c	-2.2 ^c
Skin (ex basal & squam):	2.3 ^c	2.4 ^c	2.2 ^c	-0.4 ^c	-0.3 ^c	-0.6 ^c
Melanoma of the skin	2.4 ^c	2.5 ^c	2.3 ^c	-0.3	-0.1	-0.7 ^c
Other non-epithelial skin	1.3	1.5	0.9	-0.5	-0.7	-0.2
Breast	0.2	1.0	0.4	-2.4 ^c	-0.2	-2.4 ^c
Breast (<i>in situ</i>)	5.2 ^c	4.2	5.3 ^c	-	-	-

^a The APC is the Annual Percent Change over the time interval.
SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is significantly different from zero (p<.05).

- Statistic could not be calculated.

Table I-7 - continued
 SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
 All Races, 1992-2002

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-1.0 ^c	-	-0.8 ^c	-1.0 ^c	-	-0.8 ^c
Cervix uteri	-2.9 ^c	-	-2.8 ^c	-3.3 ^c	-	-3.1 ^c
Corpus uteri	-0.4	-	-0.2	-1.6 ^c	-	-1.3 ^c
Uterus, NOS	0.9	-	1.3	0.7 ^c	-	1.1 ^c
Ovary	-1.1 ^c	-	-0.9 ^c	-0.6 ^c	-	-0.5 ^c
Vagina	-1.3	-	-1.0	-2.0 ^c	-	-1.6 ^c
Vulva	0.0	-	0.4	-0.5	-	-0.2
Other female genital system	0.5	-	0.6	3.9 ^c	-	4.0 ^c
Male Genital System:	-1.3	-1.9 ^c	-	-3.2 ^c	-3.6 ^c	-
Prostate	-1.3	-2.0 ^c	-	-3.2 ^c	-3.6 ^c	-
Testis	1.1 ^c	1.1 ^c	-	-0.4	-0.6	-
Penis	-1.0	-1.4	-	-1.0	-1.6 ^c	-
Other male genital system	0.9	0.6	-	1.7	1.5	-
Urinary System:	0.4 ^c	0.2	0.4 ^c	-0.2 ^c	-0.3 ^c	-0.4
Urinary bladder	-0.2	-0.2	-0.4 ^c	-0.3 ^c	-0.6 ^c	-0.4
Kidney & renal pelvis	1.5 ^c	1.4 ^c	1.4 ^c	-0.1	-0.1	-0.4
Ureter	-0.9	-1.3	-0.3	-2.0 ^c	-2.4 ^c	-1.5
Other urinary system	-2.0	-1.7	-2.6	6.7 ^c	9.9 ^c	3.5 ^c
Eye & Orbit	-1.1	-1.6	-0.9	-3.2 ^c	-3.7 ^c	-2.9 ^c
Brain & Nervous System: ^d	-0.6 ^c	-0.7	-0.5	-0.9 ^c	-0.7 ^c	-1.1 ^c
Brain	-0.5	-0.6	-0.6	-	-	-
Cranial nerves & other nervous system	-0.8	-2.4	0.6	-	-	-
Endocrine System:	4.0 ^c	2.7 ^c	4.5 ^c	0.1	0.8	-0.3
Thyroid	4.3 ^c	3.1 ^c	4.8 ^c	0.6	2.0 ^c	-0.1
Other endocrine & thymus	1.0	1.0	0.8	-0.7 ^c	-0.6	-0.8 ^c
Lymphoma:	0.0	-0.4	0.6 ^c	-0.9 ^c	-0.8 ^c	-1.0 ^c
Hodgkin lymphoma	-0.3	-0.1	-0.5	-3.2 ^c	-3.6 ^c	-2.8 ^c
Non-Hodgkin lymphoma	0.1	-0.5	0.8 ^c	-0.8	-0.7	-0.9
Myeloma	-0.5	-0.5	-0.8	-0.4 ^c	-0.5 ^c	-0.4
Leukemia:	-0.9 ^c	-1.1 ^c	-0.8 ^c	-0.6 ^c	-0.7 ^c	-0.6 ^c
Lymphocytic:	-1.5 ^c	-1.7 ^c	-1.4 ^c	-1.2 ^c	-1.5 ^c	-1.0 ^c
Acute lymphocytic	0.7	-0.1	1.7 ^c	-1.2 ^c	-1.6 ^c	-1.0 ^c
Chronic lymphocytic	-2.3 ^c	-2.1 ^c	-2.9 ^c	-0.9 ^c	-1.3 ^c	-0.7
Other lymphocytic	-1.5	-2.4 ^c	0.5	-3.8 ^c	-3.8 ^c	-4.2 ^c
Myeloid & Monocytic:	0.2	0.3	0.0	0.4 ^c	0.5 ^c	0.3
Acute myeloid	1.2 ^c	1.3 ^c	0.8	2.1 ^c	2.2 ^c	2.0 ^c
Chronic myeloid	-2.1 ^c	-2.2 ^c	-2.2 ^c	-5.7 ^c	-6.0 ^c	-5.6 ^c
Acute monocytic	3.0 ^c	4.4 ^c	1.2	-6.9 ^c	-5.8 ^c	-8.2 ^c
Other myeloid & monocytic	-1.1	-2.0	0.4	8.4 ^c	9.7 ^c	6.6 ^c
Other:	-3.7 ^c	-5.1 ^c	-2.3	-1.5 ^c	-1.5 ^c	-1.6 ^c
Other acute	-6.4 ^c	-7.8 ^c	-4.9 ^c	-3.6 ^c	-3.5 ^c	-3.9 ^c
Aleukemic, subleuk & NOS	-0.5	-1.9	1.0	0.7 ^c	0.4	0.9 ^c
Kaposi Sarcoma ^e	-20.0 ^c	-20.4 ^c	-6.0 ^c	-	-	-
Mesothelioma ^e	-1.1 ^c	-1.5 ^c	-0.4	-	-	-
Ill-defined & unspecified	-3.3 ^c	-3.7 ^c	-3.0 ^c	0.4	0.6	0.2

^a The APC is the Annual Percent Change over the time interval.
 SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is significantly different from zero (p<.05).

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^e Trend not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated.

Table I-8
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
Whites, 1992-2002

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-0.4 ^c	-1.3 ^c	0.2	-0.9 ^c	-1.4 ^c	-0.7 ^c
Oral Cavity & Pharynx:	-1.2 ^c	-1.5 ^c	-1.2 ^c	-2.1 ^c	-2.3 ^c	-2.3 ^c
Lip	-4.5 ^c	-5.7 ^c	-1.2	-4.8 ^c	-5.2 ^c	-5.4 ^c
Tongue	0.9 ^c	1.0 ^c	0.4	-0.9 ^c	-1.3 ^c	-0.7
Salivary gland	0.6	0.5	0.6	-1.3 ^c	-1.4 ^c	-1.7 ^c
Floor of mouth	-4.1 ^c	-4.0 ^c	-4.4 ^c	-8.7 ^c	-8.5 ^c	-9.3 ^c
Gum & other oral cavity	-2.3 ^c	-2.6 ^c	-2.1 ^c	-3.5 ^c	-4.2 ^c	-3.1 ^c
Nasopharynx	-1.8 ^c	-2.1 ^c	-1.9	-3.6 ^c	-3.7 ^c	-3.7 ^c
Tonsil	2.0 ^c	2.9 ^c	-1.8	0.0	0.1	-1.4
Oropharynx	-1.5	-2.4	0.2	-0.2	-0.4	-0.2
Hypopharynx	-3.1 ^c	-3.6 ^c	-2.5	-4.9 ^c	-5.5 ^c	-3.9 ^c
Other oral cavity & pharynx	-5.4 ^c	-6.4 ^c	-4.1 ^c	-1.7 ^c	-1.4 ^c	-2.8 ^c
Digestive System:	-0.3	-0.6 ^c	-0.2	-0.9 ^c	-1.0 ^c	-1.1 ^c
Esophagus	1.2 ^c	1.5 ^c	-0.4	1.6 ^c	1.6 ^c	0.7 ^c
Stomach	-1.6 ^c	-2.1 ^c	-1.0	-3.2 ^c	-3.6 ^c	-2.9 ^c
Small intestine	1.7 ^c	1.3	1.9 ^c	-1.5 ^c	-1.4	-1.6 ^c
Colon & Rectum:	-0.9 ^c	-1.3 ^c	-0.7 ^c	-1.9 ^c	-2.2 ^c	-1.9 ^c
Colon	-1.0 ^c	-1.4 ^c	-0.7 ^c	-	-	-
Rectum	-0.7	-1.0 ^c	-0.6	-	-	-
Anus, anal canal & anorectum	2.4 ^c	2.4 ^c	2.5 ^c	1.9 ^c	1.7 ^c	2.2 ^c
Liver & Intrahep:	3.5 ^c	2.9 ^c	3.7 ^c	2.0 ^c	2.1 ^c	1.1 ^c
Liver	4.6 ^c	3.8 ^c	5.3 ^c	1.5 ^c	1.9 ^c	0.0
Intrahep bile duct	-1.4	-2.1	-0.9	3.6 ^c	3.2 ^c	3.8 ^c
Gallbladder	-1.5 ^c	-0.9	-1.4	-2.7 ^c	-2.2 ^c	-2.7 ^c
Other biliary	0.6	0.7	0.4	-3.0 ^c	-3.2 ^c	-3.0 ^c
Pancreas	0.0	0.1	-0.3	0.1	0.0	0.0
Retroperitoneum	0.0	2.1 ^c	-1.9 ^c	-3.6 ^c	-4.0 ^c	-3.2 ^c
Peritoneum, omentum & mesentery	9.4 ^c	-1.6	10.6 ^c	7.8 ^c	-0.9	10.6 ^c
Other digestive system	4.8 ^c	3.0	5.8 ^c	8.2 ^c	8.4 ^c	7.7 ^c
Respiratory System:	-1.2 ^c	-2.2 ^c	-0.2	-0.7 ^c	-1.8 ^c	0.6 ^c
Nose, nasal cavity & middle ear	-1.0	-1.5	-1.0	-1.7 ^c	-1.5	-2.7 ^c
Larynx	-2.9 ^c	-3.3 ^c	-2.1 ^c	-1.9 ^c	-2.3 ^c	-1.5 ^c
Lung & bronchus	-1.1 ^c	-2.1 ^c	-0.1	-0.7 ^c	-1.7 ^c	0.7 ^c
Pleura	1.8	2.8	-	-5.9 ^c	-6.1 ^c	-5.8 ^c
Trachea & other respiratory organs	-2.9 ^c	-3.2 ^c	-3.5	-3.5 ^c	-3.9 ^c	-3.0 ^c
Bones & joints	-0.4	-0.8	0.2	-0.7 ^c	-1.0 ^c	-0.6
Soft tissue (incl heart)	1.4 ^c	1.7 ^c	1.1	-1.4 ^c	-1.2 ^c	-1.7 ^c
Skin (ex basal & squam):	2.8 ^c	2.8 ^c	2.8 ^c	-0.1	-0.1	-0.3
Melanoma of the skin	2.9 ^c	2.9 ^c	3.0 ^c	-0.2	0.0	-0.5 ^c
Other non-epithelial skin	1.6 ^c	1.7 ^c	1.3	0.0	-0.4	0.5
Breast	0.3	1.4	0.5	-2.6 ^c	-0.3	-2.5 ^c
Breast (<i>in situ</i>)	5.1 ^c	5.8 ^c	5.2 ^c	-	-	-

^a The APC is the Annual Percent Change over the time interval.
SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is significantly different from zero (p<.05).

- Statistic could not be calculated.

Table I-8 - continued
 SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
 Whites, 1992-2002

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-0.9 ^c	-	-0.7 ^c	-0.9 ^c	-	-0.7 ^c
Cervix uteri	-2.4 ^c	-	-2.2 ^c	-2.9 ^c	-	-2.7 ^c
Corpus uteri	-0.6 ^c	-	-0.3	-1.7 ^c	-	-1.4 ^c
Uterus, NOS	0.7	-	1.4	0.6 ^c	-	1.0 ^c
Ovary	-1.0 ^c	-	-0.8 ^c	-0.6 ^c	-	-0.4
Vagina	-0.6	-	-0.3	-1.9 ^c	-	-1.4
Vulva	0.7	-	1.2	-0.3	-	0.1
Other female genital system	0.6	-	0.7	4.2 ^c	-	4.3 ^c
Male Genital System:	-1.3	-2.0	-	-3.2 ^c	-3.6 ^c	-
Prostate	-1.4	-2.1 ^c	-	-3.3 ^c	-3.7 ^c	-
Testis	1.3 ^c	1.3 ^c	-	-0.5	-0.7	-
Penis	-0.7	-1.3	-	-0.6	-1.0	-
Other male genital system	0.6	0.2	-	1.7	1.2	-
Urinary System:	0.5 ^c	0.3	0.5 ^c	-0.1	-0.2 ^c	-0.3
Urinary bladder	0.0	-0.1	-0.2	-0.1	-0.5 ^c	-0.3
Kidney & renal pelvis	1.7 ^c	1.6 ^c	1.5 ^c	-0.1	-0.1	-0.4
Ureter	-0.9	-1.3	-0.2	-1.8 ^c	-2.2 ^c	-1.3
Other urinary system	-1.3	-1.3	-1.8	7.9 ^c	11.3 ^c	4.3 ^c
Eye & Orbit	-0.7	-1.6	-0.1	-3.3 ^c	-3.7 ^c	-3.1 ^c
Brain & Nervous System: ^d	-0.3	-0.4	-0.1	-0.8 ^c	-0.7 ^c	-1.0 ^c
Brain	-0.2	-0.3	-0.2	-	-	-
Cranial nerves & other nervous system	-0.7	-2.6	1.0	-	-	-
Endocrine System:	4.4 ^c	3.1 ^c	5.1 ^c	0.0	0.8	-0.5
Thyroid	4.7 ^c	3.4 ^c	5.2 ^c	0.6	2.0 ^c	-0.1
Other endocrine & thymus	1.5	1.4	1.5	-0.8	-0.6	-1.0
Lymphoma:	0.0	-0.4	0.6 ^c	-0.9 ^c	-0.8 ^c	-1.0 ^c
Hodgkin lymphoma	-0.3	-0.3	-0.4	-3.1 ^c	-3.3 ^c	-2.7 ^c
Non-Hodgkin lymphoma	0.1	-0.4	0.8 ^c	-0.8	-0.7	-0.9
Myeloma	-0.4	-0.3	-0.8	-0.3	-0.3	-0.4 ^c
Leukemia:	-0.8 ^c	-1.1 ^c	-0.5	-0.5 ^c	-0.6 ^c	-0.5 ^c
Lymphocytic:	-1.3 ^c	-1.6 ^c	-1.1	-1.1 ^c	-1.4 ^c	-0.9 ^c
Acute lymphocytic	1.0	0.1	2.3 ^c	-1.1 ^c	-1.4 ^c	-0.8
Chronic lymphocytic	-2.2 ^c	-2.0 ^c	-2.8 ^c	-0.8 ^c	-1.1 ^c	-0.7
Other lymphocytic	-1.3	-2.4 ^c	1.1	-3.8 ^c	-3.8 ^c	-4.2 ^c
Myeloid & Monocytic:	0.3	0.3	0.2	0.5 ^c	0.5	0.4 ^c
Acute myeloid	1.3 ^c	1.3 ^c	1.2 ^c	2.2 ^c	2.2 ^c	2.1 ^c
Chronic myeloid	-2.1 ^c	-2.2 ^c	-2.2 ^c	-5.8 ^c	-6.2 ^c	-5.6 ^c
Acute monocytic	3.7 ^c	4.6 ^c	2.4	-6.9 ^c	-5.7 ^c	-8.3 ^c
Other myeloid & monocytic	-1.2	-1.9	0.0	8.6 ^c	9.7 ^c	6.7 ^c
Other:	-3.6 ^c	-5.4 ^c	-1.7	-1.4 ^c	-1.5 ^c	-1.6 ^c
Other acute	-6.1 ^c	-8.0 ^c	-3.9 ^c	-3.6 ^c	-3.4 ^c	-3.9 ^c
Aleukemic, subleuk & NOS	-0.5	-2.3 ^c	1.3	0.9 ^c	0.5	1.1 ^c
Kaposi Sarcoma ^e	-22.0 ^c	-22.4 ^c	-6.9 ^c	-	-	-
Mesothelioma ^e	-0.7	-1.3 ^c	0.0	-	-	-
Ill-defined & unspecified	-3.0 ^c	-3.6 ^c	-2.7 ^c	0.6	0.8	0.4

^a The APC is the Annual Percent Change over the time interval.
 SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is significantly different from zero (p<.05).

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^e Trend not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated.

Table I-9
SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
Blacks, 1992-2002

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
All Sites	-1.0 ^c	-1.7 ^c	-0.2	-1.5 ^c	-2.0 ^c	-0.8 ^c
Oral Cavity & Pharynx:	-2.8 ^c	-3.1 ^c	-1.7 ^c	-4.3 ^c	-4.6 ^c	-3.5 ^c
Lip	-1.2	-	-	-	-	-
Tongue	-1.5	-3.0 ^c	1.7	-5.9 ^c	-5.9 ^c	-5.9 ^c
Salivary gland	-1.4	-1.8	-0.6	-1.4	-3.6	1.8
Floor of mouth	-5.7 ^c	-5.6 ^c	-5.0	-9.9 ^c	-9.9 ^c	-8.9 ^c
Gum & other oral cavity	-3.0 ^c	-3.5 ^c	-1.6	-6.1 ^c	-6.1 ^c	-5.8 ^c
Nasopharynx	-2.1	-2.7	-0.7	-1.1	-3.1 ^c	3.2
Tonsil	-1.5	-0.7	-3.7	-4.5 ^c	-4.5 ^c	-4.3 ^c
Oropharynx	-2.1	-3.1	4.3	-1.8 ^c	-1.8 ^c	-2.0
Hypopharynx	-5.0 ^c	-4.4 ^c	-6.2 ^c	-6.8 ^c	-7.5 ^c	-4.1
Other oral cavity & pharynx	-5.3 ^c	-2.9	-	-3.1 ^c	-3.1 ^c	-3.1 ^c
Digestive System:	-0.6 ^c	-1.0 ^c	-0.2	-1.3 ^c	-1.5 ^c	-1.0 ^c
Esophagus	-5.1 ^c	-5.7 ^c	-4.0 ^c	-4.1 ^c	-4.4 ^c	-3.3 ^c
Stomach	-1.5 ^c	-2.8 ^c	0.0	-2.6 ^c	-3.0 ^c	-2.1 ^c
Small intestine	3.9 ^c	3.7 ^c	4.6 ^c	-0.5	-0.7	-0.2
Colon & Rectum:	-0.3	-0.5	-0.1	-0.8 ^c	-0.8 ^c	-0.9 ^c
Colon	-0.3	-0.4	-0.2	-	-	-
Rectum	-0.4	-1.0	0.4	-	-	-
Anus, anal canal & anorectum	2.3	2.3	2.5	-1.8 ^c	-1.5	-2.6
Liver & Intrahep:	3.5 ^c	4.5 ^c	1.4	1.3 ^c	1.3 ^c	0.7
Liver	3.7 ^c	4.8 ^c	1.4	0.7	1.0	-0.3
Intrahep bile duct	1.4	1.3	1.7	4.8 ^c	4.0 ^c	5.5 ^c
Gallbladder	-0.8	-3.9	0.2	-0.2	-0.4	-0.2
Other biliary	0.6	1.0	0.0	-1.9 ^c	0.3	-2.9 ^c
Pancreas	-1.9 ^c	-2.5 ^c	-1.6 ^c	-1.1 ^c	-1.5 ^c	-0.8 ^c
Retroperitoneum	-2.1	-1.9	-1.1	-6.4 ^c	-2.3	-9.3 ^c
Peritoneum, omentum & mesentery	6.7	-	8.4 ^c	5.3 ^c	-0.8	6.9 ^c
Other digestive system	9.3 ^c	1.9	14.7 ^c	7.1 ^c	8.4 ^c	6.7
Respiratory System:	-1.5 ^c	-2.5 ^c	0.3	-1.6 ^c	-2.5 ^c	0.3
Nose, nasal cavity & middle ear	-3.1	-1.6	-4.4 ^c	-6.5 ^c	-7.3 ^c	-6.4 ^c
Larynx	-3.2 ^c	-3.2 ^c	-3.0	-2.8 ^c	-2.9 ^c	-2.3 ^c
Lung & bronchus	-1.4 ^c	-2.5 ^c	0.5	-1.5 ^c	-2.5 ^c	0.4 ^c
Pleura	-	-	-	-7.6 ^c	-8.8 ^c	-4.6
Trachea & other respiratory organs	-0.5	-	-	-7.2 ^c	-4.7 ^c	-10.5 ^c
Bones & joints	-1.5	-0.9	-3.1	-3.1 ^c	-3.7 ^c	-3.2
Soft tissue (incl heart)	1.0	2.5	-0.2	-3.1 ^c	-0.3	-4.9 ^c
Skin (ex basal & squam):	0.5	1.5	-0.7	-3.8 ^c	-3.5 ^c	-4.0 ^c
Melanoma of the skin	-0.7	0.3	-1.4	-1.5	-0.5	-2.0
Other non-epithelial skin	1.2	2.2	0.1	-5.2 ^c	-4.6 ^c	-6.6 ^c
Breast	-0.2	4.0	-0.2	-1.2 ^c	0.4	-1.2 ^c
Breast (<i>in situ</i>)	5.3 ^c	-	5.4 ^c	-	-	-

^a The APC is the Annual Percent Change over the time interval.
SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is significantly different from zero (p<.05).

- Statistic could not be calculated.

Table I-9 - continued
 SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX
 Blacks, 1992-2002

Site	Incidence ^a			US Mortality ^b		
	Total APC	Males APC	Females APC	Total APC	Males APC	Females APC
Female Genital System:	-1.0 ^c	-	-0.9 ^c	-1.7 ^c	-	-1.7 ^c
Cervix uteri	-3.8 ^c	-	-3.8 ^c	-4.9 ^c	-	-4.9 ^c
Corpus uteri	1.6 ^c	-	1.8 ^c	-1.0	-	-0.9
Uterus, NOS	1.1	-	1.3	1.1 ^c	-	1.2 ^c
Ovary	-1.6 ^c	-	-1.6 ^c	-0.9 ^c	-	-0.8 ^c
Vagina	-2.4	-	-2.2	-2.9 ^c	-	-2.9 ^c
Vulva	-1.9	-	-1.8	-1.6	-	-1.7
Other female genital system	-2.0	-	-1.3	1.9	-	2.0
Male Genital System:	-1.4 ^c	-1.9 ^c	-	-2.6 ^c	-2.5 ^c	-
Prostate	-1.4 ^c	-1.9 ^c	-	-2.6 ^c	-2.5 ^c	-
Testis	5.4 ^c	5.5 ^c	-	2.5	2.6	-
Penis	-1.8	-0.9	-	-5.5 ^c	-6.4 ^c	-
Other male genital system	-	-	-	2.9	4.4	-
Urinary System:	1.1 ^c	0.8	1.7 ^c	-0.7 ^c	-1.0 ^c	-0.4
Urinary bladder	0.2	-0.2	0.9	-1.3 ^c	-2.0 ^c	-0.6
Kidney & renal pelvis	2.3 ^c	2.2 ^c	2.5 ^c	0.0	0.1	0.0
Ureter	2.4	1.7	5.2	-6.1 ^c	-8.9 ^c	-3.4
Other urinary system	-4.1 ^c	-2.9	-4.4	-0.5	-1.0	-0.1
Eye & Orbit	-3.3	0.4	-5.6	0.7	2.4	0.3
Brain & Nervous System: ^d	-0.7	0.0	-1.3	-0.6 ^c	-0.8 ^c	-0.6
Brain	-0.6	0.2	-1.4	-	-	-
Cranial nerves & other nervous system	-1.7	-1.5	-1.3	-	-	-
Endocrine System:	3.1 ^c	1.4	3.5 ^c	0.7	0.7	0.7
Thyroid	3.9 ^c	1.0	4.5 ^c	2.1 ^c	3.8 ^c	1.5
Other endocrine & thymus	-1.1	1.8	-4.2 ^c	-1.1 ^c	-1.9 ^c	-0.4
Lymphoma:	0.3	-0.8	1.9 ^c	-0.8	-1.0	-0.5
Hodgkin lymphoma	0.2	1.4	-1.1	-4.3 ^c	-4.7 ^c	-3.8 ^c
Non-Hodgkin lymphoma	0.3	-1.2	2.5 ^c	-0.5	-0.6	-0.3
Myeloma	-1.3 ^c	-0.7	-1.8 ^c	-0.8 ^c	-1.2 ^c	-0.5
Leukemia:	-1.4	-1.6	-1.2	-1.0 ^c	-1.1 ^c	-0.7 ^c
Lymphocytic:	-3.2 ^c	-3.5	-2.5	-1.8 ^c	-2.4 ^c	-0.8
Acute lymphocytic	-1.8	-3.7	-0.4	-2.5	-3.3 ^c	-1.8
Chronic lymphocytic	-3.8 ^c	-3.6	-3.5 ^c	-1.6 ^c	-2.3 ^c	-0.3
Other lymphocytic	-1.1	-2.1	-	-2.6	-1.6	-3.7
Myeloid & Monocytic:	0.8	1.2	0.2	-0.2	0.0	-0.5
Acute myeloid	2.5	4.0 ^c	0.9	1.7 ^c	1.8 ^c	1.5 ^c
Chronic myeloid	-3.0	-4.1	-2.5	-5.4 ^c	-4.9 ^c	-5.9 ^c
Acute monocytic	0.8	-	-	-8.1	-	-4.4
Other myeloid & monocytic	5.0	-	6.2	8.4 ^c	9.6 ^c	5.8 ^c
Other:	-5.2 ^c	-7.8	-3.9	-1.2 ^c	-1.3	-1.1
Other acute	-5.1	-5.5	-7.8	-3.5 ^c	-3.5 ^c	-3.2
Aleukemic, subleuk & NOS	-4.9	-10.2	0.2	0.4	0.3	0.5
Kaposi Sarcoma ^e	-12.4 ^c	-12.7 ^c	-7.2	-	-	-
Mesothelioma ^e	-4.1	-3.7	-2.5	-	-	-
Ill-defined & unspecified	-3.7 ^c	-3.7 ^c	-3.7 ^c	-0.6	-0.5	-0.6

^a The APC is the Annual Percent Change over the time interval.
 SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is significantly different from zero (p<.05).

^d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^e Trend not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated.

Table I-10

AGE DISTRIBUTION (%) OF INCIDENCE CASES BY SITE, 1998-2002

All Races, Both Sexes

Site	Age								All Ages	Cases
	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+		
All Sites	1.1	2.9	6.2	13.5	20.2	26.3	22.5	7.4	100.0%	833,460
Oral Cavity & Pharynx:	0.6	2.7	7.7	20.2	23.0	23.0	17.1	5.8	100.0%	18,840
Lip	0.1	2.0	8.1	12.1	16.3	25.0	25.1	11.2	100.0%	1,627
Tongue	0.1	2.4	7.8	22.6	24.2	22.4	15.9	4.6	100.0%	4,705
Salivary gland	1.8	7.1	9.4	15.4	18.1	19.4	19.3	9.6	100.0%	2,145
Floor of mouth	0.1	0.4	4.7	20.5	28.6	24.4	16.1	5.3	100.0%	1,387
Gum & other oral cavity	0.7	2.3	5.3	13.8	19.9	25.2	23.6	9.1	100.0%	2,892
Nasopharynx	2.5	7.8	17.1	24.7	20.6	16.4	8.3	2.5	100.0%	1,314
Tonsil	0.0	0.9	9.3	32.3	27.8	18.9	9.4	1.5	100.0%	2,389
Oropharynx	0.0	0.8	3.2	20.7	28.2	27.1	15.6	4.3	100.0%	531
Hypopharynx	0.0	0.1	3.6	18.0	25.3	31.5	18.4	3.0	100.0%	1,408
Other oral cavity & pharynx	1.4	0.2	2.7	15.4	26.9	30.8	18.1	4.5	100.0%	442
Digestive System:	0.2	1.0	3.8	11.2	17.6	26.6	28.0	11.7	100.0%	159,373
Esophagus	0.0	0.5	2.7	12.1	22.0	30.3	24.6	7.8	100.0%	7,911
Stomach	0.1	1.6	4.6	10.3	16.3	26.3	28.2	12.7	100.0%	15,392
Small intestine	0.3	1.9	6.0	15.6	20.6	24.9	23.0	7.7	100.0%	3,096
Colon & Rectum:	0.0	0.9	3.5	10.4	17.0	26.3	29.2	12.6	100.0%	92,665
Colon	0.0	0.8	3.0	8.8	15.6	26.4	31.2	14.2	100.0%	66,809
Rectum	0.1	1.3	4.9	14.4	20.8	26.0	23.9	8.6	100.0%	25,856
Colon & Rectum (Male)	0.0	1.0	3.7	11.3	19.5	28.5	27.3	8.8	100.0%	46,471
Colon & Rectum (Female)	0.0	0.9	3.4	9.4	14.5	24.1	31.1	16.5	100.0%	46,194
Anus, anal canal & anorectum	0.0	1.9	13.8	22.4	18.0	20.0	16.9	7.1	100.0%	2,509
Liver & Intrahep:	1.2	1.2	4.2	18.2	21.0	26.4	21.2	6.6	100.0%	10,942
Liver	1.4	1.2	4.4	19.1	21.5	26.5	20.1	5.7	100.0%	9,548
Intrahep bile duct	0.0	0.9	3.2	11.5	17.1	25.6	28.8	12.8	100.0%	1,394
Gallbladder	0.0	0.4	2.5	9.2	15.6	27.2	30.5	14.6	100.0%	2,141
Other biliary	0.1	0.7	2.9	8.6	15.9	27.3	30.3	14.0	100.0%	2,758
Pancreas	0.1	0.5	2.7	9.8	17.5	27.9	29.4	12.2	100.0%	19,243
Retroperitoneum	9.8	6.2	9.3	15.1	16.0	20.5	19.4	3.7	100.0%	775
Peritoneum, omentum & mesentery	0.7	1.7	4.9	10.8	23.1	31.2	22.7	5.0	100.0%	1,058
Other digestive system	0.0	1.1	3.2	10.4	15.5	24.6	27.7	17.4	100.0%	883
Respiratory System:	0.1	0.4	2.3	9.3	21.1	32.8	27.2	6.7	100.0%	114,250
Nose, nasal cavity & middle ear	3.1	4.4	8.1	16.5	18.9	21.2	20.7	7.2	100.0%	1,191
Larynx	0.0	0.4	4.0	15.5	27.5	31.0	17.8	3.8	100.0%	6,445
Lung & bronchus	0.0	0.3	2.1	8.9	20.8	33.1	27.9	6.9	100.0%	106,208
Lung & bronchus (Male)	0.0	0.2	2.0	8.9	21.4	33.8	27.5	6.1	100.0%	58,361
Lung & bronchus (Female)	0.0	0.3	2.4	8.8	20.0	32.3	28.4	7.8	100.0%	47,847
Pleura	1.6	4.8	9.5	6.3	19.0	28.6	19.0	11.1	100.0%	63
Trachea & other respiratory organs	15.5	22.4	12.0	10.5	11.4	14.3	10.2	3.8	100.0%	343
Bones & joints	28.9	17.5	11.8	12.4	10.9	8.3	7.0	3.1	100.0%	1,632
Soft tissue (incl heart)	10.9	11.4	11.9	14.7	14.3	15.6	15.2	5.9	100.0%	5,298
Skin (ex basal & squam):	0.9	9.3	14.4	18.8	17.3	18.0	15.7	5.6	100.0%	34,843
Melanoma of the skin	0.8	9.4	15.0	19.4	17.8	17.9	14.8	5.0	100.0%	31,589
Other non-epithelial skin	1.8	8.5	9.2	12.2	12.5	19.1	24.6	12.1	100.0%	3,254
Breast (Female)	0.0	2.0	10.7	22.2	22.2	20.7	16.7	5.6	100.0%	131,142
Breast (Female <i>-in situ</i>)	0.0	0.9	11.5	28.6	24.2	19.9	12.7	2.2	100.0%	29,912

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia).

Table I-10 - continued

AGE DISTRIBUTION (%) OF INCIDENCE CASES BY SITE, 1998-2002

All Races, Both Sexes

Site	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
Female Genital System:	0.5	4.7	10.8	19.2	21.9	20.5	16.7	5.6	100.0%	49,631
Cervix uteri	0.2	15.6	26.8	22.7	13.9	10.9	7.1	2.8	100.0%	8,831
Corpus uteri	0.0	1.5	6.4	18.8	26.6	24.0	17.7	4.9	100.0%	23,096
Uterus, NOS	0.7	3.3	8.2	16.1	16.9	15.2	20.8	18.9	100.0%	461
Ovary	1.3	3.5	8.4	19.0	20.8	21.1	19.4	6.6	100.0%	13,587
Vagina	1.1	1.4	7.5	12.9	18.4	24.2	22.2	12.2	100.0%	697
Vulva	0.1	2.9	9.3	14.9	13.5	19.2	25.6	14.5	100.0%	2,227
Other female genital system	1.5	9.0	8.5	16.7	21.0	21.3	17.1	4.9	100.0%	732
Male Genital System:	0.2	1.8	1.8	8.2	25.1	36.0	22.4	4.6	100.0%	138,267
Prostate	0.0	0.0	0.5	8.0	26.1	37.5	23.2	4.7	100.0%	132,081
Testis	5.5	46.1	32.3	11.9	2.6	1.0	0.6	0.1	100.0%	5,344
Penis	0.2	2.1	7.1	10.5	17.7	25.8	26.3	10.3	100.0%	581
Other male genital system	3.4	2.7	5.7	12.6	19.5	24.9	22.6	8.4	100.0%	261
Urinary System:	0.7	0.9	3.8	10.8	18.9	27.8	27.8	9.4	100.0%	57,488
Urinary bladder	0.1	0.6	2.4	8.0	16.8	28.8	32.0	11.4	100.0%	35,403
Kidney & renal pelvis	1.8	1.4	6.3	15.8	22.8	25.9	20.2	5.7	100.0%	20,676
Ureter	0.0	0.5	1.0	4.5	15.5	31.2	35.2	12.0	100.0%	888
Other urinary system	0.4	1.3	3.3	9.8	18.2	25.3	27.3	14.4	100.0%	521
Eye & Orbit	16.1	3.3	7.7	14.8	16.5	19.5	16.2	6.0	100.0%	1,388
Brain & Nervous System:	13.8	10.0	11.7	14.4	15.4	17.1	14.2	3.6	100.0%	11,757
Brain	13.4	9.8	11.5	14.3	15.6	17.4	14.5	3.6	100.0%	11,019
Cranial nerves & other nervous system	19.5	11.9	14.5	15.3	13.1	12.2	10.2	3.3	100.0%	738
Endocrine System:	4.1	19.4	22.2	21.7	14.6	10.3	6.3	1.5	100.0%	15,804
Thyroid	2.3	20.2	23.3	22.1	14.6	10.0	6.0	1.4	100.0%	14,559
Other endocrine & thymus	24.9	9.6	9.3	16.3	15.2	13.3	9.1	2.4	100.0%	1,245
Lymphoma:	3.2	8.4	10.0	13.7	16.0	20.9	20.7	7.1	100.0%	39,411
Hodgkin lymphoma	12.5	32.9	19.0	12.0	7.8	8.4	5.8	1.6	100.0%	5,180
Non-Hodgkin lymphoma	1.8	4.7	8.6	14.0	17.2	22.8	23.0	7.9	100.0%	34,231
Myeloma	0.0	0.6	3.4	11.2	19.0	28.5	27.8	9.4	100.0%	9,708
Leukemia:	11.4	5.2	5.9	9.7	13.9	20.5	23.2	10.1	100.0%	21,859
Lymphocytic:	18.9	3.2	4.2	9.3	14.8	19.6	20.7	9.2	100.0%	10,044
Acute lymphocytic	63.6	9.7	5.8	6.1	5.3	4.5	3.4	1.5	100.0%	2,972
Chronic lymphocytic	0.0	0.2	2.4	9.4	18.9	26.9	29.2	12.9	100.0%	6,264
Other lymphocytic	0.7	2.6	12.4	20.2	18.6	18.4	18.6	8.5	100.0%	808
Myeloid & Monocytic:	5.3	7.5	7.8	10.7	13.7	21.4	24.4	9.1	100.0%	10,425
Acute myeloid	6.3	7.2	7.0	10.0	13.9	22.4	24.6	8.7	100.0%	6,789
Chronic myeloid	2.4	8.6	10.3	12.4	13.4	19.5	23.6	9.7	100.0%	2,875
Acute monocytic	10.4	7.9	6.6	13.9	15.4	18.9	19.1	7.9	100.0%	482
Other myeloid & monocytic	4.3	2.5	5.0	6.5	10.8	22.6	36.2	12.2	100.0%	279
Other:	3.0	2.6	3.4	5.0	8.6	19.7	32.8	24.8	100.0%	1,390
Other acute	4.5	3.2	3.0	4.6	8.5	19.9	34.2	22.1	100.0%	693
Aleukemic, subleuk & NOS	1.6	2.0	3.7	5.5	8.8	19.5	31.4	27.5	100.0%	697
Kaposi Sarcoma	0.1	24.1	39.4	16.4	5.1	4.9	6.2	3.9	100.0%	1,729
Mesothelioma	0.1	1.0	2.6	7.5	15.1	29.6	35.6	8.4	100.0%	1,776
Ill-defined & unspecified	0.4	1.1	3.3	9.7	15.6	24.1	29.9	15.9	100.0%	18,351

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia).

Table I-11
MEDIAN AGE OF CANCER PATIENTS AT DIAGNOSIS^a, 1998-2002
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	67.0	68.0	66.0	68.0	68.0	67.0	64.0	64.0	62.0
Oral Cavity & Pharynx:	63.0	61.0	66.0	64.0	62.0	68.0	57.0	57.0	56.0
Lip	70.0	68.0	74.0	70.0	68.0	75.0	56.5	-	-
Tongue	62.0	60.0	65.0	62.0	61.0	66.0	57.0	57.0	59.0
Salivary gland	63.0	66.0	60.0	65.0	67.0	62.5	55.5	56.5	53.5
Floor of mouth	63.0	61.0	67.0	64.0	62.0	69.0	56.5	57.0	56.0
Gum & other oral cavity	68.0	65.0	72.0	69.0	66.0	73.0	58.0	58.0	56.0
Nasopharynx	53.0	54.0	53.0	58.0	57.0	62.0	47.5	50.0	42.0
Tonsil	57.0	56.0	61.0	57.0	56.0	62.0	56.0	56.0	55.0
Oropharynx	63.0	62.0	67.5	65.0	63.0	68.0	60.0	59.0	-
Hypopharynx	66.0	65.0	68.0	67.0	66.0	69.0	59.0	59.5	57.0
Other oral cavity & pharynx	66.0	64.0	69.0	66.0	65.0	70.0	62.0	60.0	-
Digestive System:	71.0	69.0	73.0	72.0	70.0	74.0	67.0	65.0	69.0
Esophagus	69.0	68.0	73.0	70.0	68.0	74.0	64.0	63.0	67.0
Stomach	72.0	70.0	74.0	72.0	71.0	74.0	70.0	67.0	72.0
Small intestine	67.0	66.0	69.0	68.0	66.5	69.0	64.5	63.0	65.5
Colon & Rectum:	72.0	70.0	74.0	73.0	71.0	75.0	67.0	66.0	68.0
Colon	73.0	71.0	75.0	74.0	72.0	76.0	68.0	67.0	70.0
Rectum	68.0	67.0	70.0	69.0	68.0	71.0	63.0	63.0	64.0
Anus, anal canal & anorectum	61.0	57.0	64.0	62.0	59.0	65.0	52.0	49.0	56.0
Liver & Intrahep:	66.0	64.0	71.0	68.0	65.0	72.0	60.0	58.0	66.0
Liver	65.5	63.0	70.0	67.0	65.0	72.0	59.0	57.0	66.0
Intrahep bile duct	71.0	70.0	74.0	72.0	70.0	75.0	66.0	66.5	66.0
Gallbladder	73.0	73.0	73.0	73.0	74.0	73.0	70.0	70.0	70.0
Other biliary	73.0	71.0	74.0	73.0	72.0	75.0	70.0	67.0	73.0
Pancreas	72.0	70.0	74.0	73.0	70.0	75.0	68.0	65.5	71.0
Retropertoneum	60.0	60.0	61.5	61.0	60.0	63.5	54.0	53.0	55.0
Peritoneum, omentum & mesentery	67.0	63.0	68.0	68.0	64.0	68.0	66.0	-	66.0
Other digestive system	73.0	71.0	75.0	73.0	72.0	75.0	69.0	63.0	72.0
Respiratory System:	70.0	70.0	70.0	71.0	70.0	71.0	66.0	65.0	67.0
Nose, nasal cavity & middle ear	64.0	61.0	67.0	64.0	61.0	67.0	62.0	61.0	62.0
Larynx	65.0	65.0	65.0	66.0	66.0	66.0	62.0	62.0	62.0
Lung & bronchus	70.0	70.0	71.0	71.0	71.0	71.0	66.0	66.0	67.0
Pleura	67.0	67.0	-	66.0	65.0	-	-	-	-
Trachea & other respiratory organs	45.0	38.5	59.0	42.0	37.0	57.0	56.5	-	-
Bones & joints	38.0	34.0	42.0	39.0	36.0	43.0	32.0	29.0	33.0
Soft tissue (incl heart)	55.0	55.0	56.0	57.0	57.0	56.0	48.0	44.0	52.0
Skin (ex basal & squam):	58.0	61.0	54.0	58.0	62.0	54.0	53.0	56.0	51.0
Melanoma of the skin	57.0	61.0	53.0	57.0	61.0	53.0	60.0	61.0	56.5
Other non-epithelial skin	68.0	70.0	65.0	70.0	71.0	68.0	47.0	47.0	46.0
Breast	61.0	67.0	61.0	62.0	68.0	62.0	57.0	60.5	57.0
Breast (<i>in situ</i>)	58.0	58.5	58.0	58.0	59.0	58.0	57.0	-	57.0

^a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
 - Statistic could not be calculated. Less than 25 cases were diagnosed during the time interval.

Table I-11 - continued
MEDIAN AGE OF CANCER PATIENTS AT DIAGNOSIS^a, 1998-2002
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	61.0	-	61.0	62.0	-	62.0	60.0	-	60.0
Cervix uteri	47.0	-	47.0	47.0	-	47.0	49.0	-	49.0
Corpus uteri	63.0	-	63.0	64.0	-	64.0	63.0	-	63.0
Uterus, NOS	69.0	-	69.0	71.0	-	71.0	60.5	-	60.5
Ovary	63.0	-	63.0	64.0	-	64.0	62.0	-	62.0
Vagina	68.0	-	68.0	69.0	-	69.0	64.5	-	64.5
Vulva	70.0	-	70.0	71.0	-	71.0	55.0	-	55.0
Other female genital system	61.0	-	61.0	63.0	-	63.0	49.0	-	49.0
Male Genital System:	68.0	68.0	-	68.0	68.0	-	65.0	65.0	-
Prostate	69.0	69.0	-	69.0	69.0	-	66.0	66.0	-
Testis	34.0	34.0	-	34.0	34.0	-	35.0	35.0	-
Penis	69.0	69.0	-	69.0	69.0	-	70.0	70.0	-
Other male genital system	67.0	67.0	-	68.0	68.0	-	-	-	-
Urinary System:	70.0	70.0	71.0	71.0	70.0	72.0	65.0	65.0	67.0
Urinary bladder	73.0	72.0	74.0	73.0	72.0	74.0	71.0	69.0	73.0
Kidney & renal pelvis	65.0	64.0	67.0	66.0	65.0	68.0	61.0	60.0	62.0
Ureter	74.0	72.0	76.0	74.0	72.0	77.0	69.0	65.0	-
Other urinary system	72.0	72.0	71.0	73.0	73.0	74.0	66.0	67.5	63.0
Eye & Orbit	59.0	57.0	61.0	60.0	58.0	62.0	3.0	-	-
Brain & Nervous System:	55.0	54.0	56.0	56.0	55.0	57.0	47.0	46.0	48.5
Brain	55.0	54.0	56.0	56.0	55.0	57.0	47.0	46.0	48.0
Cranial nerves & other nervous system	48.0	45.0	49.0	47.0	45.0	49.0	49.0	48.5	49.0
Endocrine System:	46.0	50.5	45.0	46.0	51.0	45.0	49.0	51.0	48.0
Thyroid	46.0	51.0	45.0	46.0	51.0	45.0	48.5	52.0	48.0
Other endocrine & thymus	48.0	46.0	49.0	48.0	47.0	50.0	49.0	47.0	49.0
Lymphomas:	64.0	61.0	67.0	65.0	62.0	68.0	51.0	50.0	53.0
Hodgkin lymphoma	37.0	38.0	35.0	37.0	39.0	35.0	35.0	37.0	31.5
Non-Hodgkin lymphoma	66.0	64.0	69.0	67.0	65.0	70.0	55.0	52.0	58.0
Myeloma	70.0	69.0	72.0	71.0	70.0	73.0	67.0	66.0	68.0
Leukemia:	67.0	66.0	68.0	68.0	67.0	69.0	61.0	60.0	64.0
Lymphocytic:	64.0	63.0	66.0	65.0	64.0	67.0	62.0	61.0	64.0
Acute lymphocytic	11.0	12.0	10.0	11.0	12.0	10.0	13.0	13.0	13.0
Chronic lymphocytic	72.0	70.0	74.5	73.0	71.0	75.0	68.0	68.0	71.0
Other lymphocytic	62.5	60.0	68.0	63.0	60.0	69.0	65.0	64.5	-
Myeloid & Monocytic:	67.0	67.0	68.0	69.0	68.0	69.0	60.0	58.0	65.0
Acute myeloid	68.0	68.0	68.0	69.0	68.0	69.0	62.0	59.5	65.0
Chronic myeloid	66.0	66.0	67.0	68.0	68.0	70.0	57.0	53.5	60.0
Acute monocytic	61.5	63.5	60.0	64.0	65.0	61.0	-	-	-
Other myeloid & monocytic	74.0	73.0	76.0	74.5	73.0	76.0	74.0	-	-
Other:	77.0	75.0	79.0	78.0	76.0	80.0	67.0	67.0	68.0
Other acute	76.0	75.0	78.0	77.0	75.0	79.0	69.0	68.0	-
Aleukemic, subleuk & NOS	77.0	75.0	80.0	78.0	76.0	81.0	58.0	58.0	61.5
Kaposi Sarcoma	40.0	40.0	76.0	42.0	41.0	79.0	37.0	37.0	-
Mesothelioma	73.0	74.0	70.0	74.0	74.0	71.0	68.0	71.0	-
Ill-defined & unspecified	73.0	71.0	75.0	74.0	72.0	76.0	67.0	64.0	70.0

^a SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).
 - Statistic could not be calculated. Less than 25 cases were diagnosed during the time interval.

Table I-12

AGE DISTRIBUTION (%) OF DEATHS BY SITE, 1998-2002

All Races, Both Sexes

Site	Age								All Ages	Cases
	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+		
All Sites	0.4	0.9	3.0	8.7	16.3	27.2	29.7	13.8	100.0%	2,755,502
Oral Cavity & Pharynx:	0.2	0.9	3.7	13.9	22.3	25.6	22.5	10.9	100.0%	38,381
Lip	0.3	1.1	3.3	7.2	12.5	20.6	29.8	25.1	100.0%	359
Tongue	0.1	1.5	4.7	14.7	23.3	24.6	21.6	9.6	100.0%	8,974
Salivary gland	0.1	0.9	3.8	9.6	15.4	22.6	28.7	18.8	100.0%	3,412
Floor of mouth	0.0	0.0	3.5	15.7	25.7	29.7	18.4	6.9	100.0%	821
Gum & other oral cavity	0.5	0.5	2.1	10.2	16.8	24.3	26.4	19.3	100.0%	6,120
Nasopharynx	1.1	3.4	8.9	19.2	22.6	21.7	17.6	5.6	100.0%	3,242
Tonsil	0.0	0.3	4.8	21.0	27.3	25.7	16.7	4.3	100.0%	2,881
Oropharynx	0.1	0.1	2.5	15.7	24.6	27.1	21.3	8.6	100.0%	2,921
Hypopharynx	0.0	0.1	2.3	13.5	28.5	30.8	19.1	5.8	100.0%	1,806
Other oral cavity & pharynx	0.0	0.2	2.3	12.5	24.2	28.6	23.4	8.7	100.0%	7,845
Digestive System:	0.1	0.5	2.5	8.6	15.6	26.2	30.3	16.2	100.0%	654,767
Esophagus	0.0	0.3	2.4	11.0	21.1	30.4	25.9	9.0	100.0%	61,142
Stomach	0.0	1.2	3.8	8.8	14.4	24.5	30.4	16.9	100.0%	62,830
Small intestine	0.0	0.9	4.3	11.8	16.9	25.5	28.1	12.5	100.0%	5,249
Colon & Rectum:	0.0	0.6	2.3	7.4	14.0	24.7	31.3	19.8	100.0%	285,040
Colon & Rectum (Male)	0.0	0.6	2.6	8.3	16.5	27.9	30.5	13.5	100.0%	141,520
Colon & Rectum (Female)	0.0	0.5	2.1	6.4	11.5	21.5	32.0	25.9	100.0%	143,520
Anus, anal canal & anorectum	0.0	0.9	8.8	17.2	18.8	21.8	21.2	11.4	100.0%	2,431
Liver & Intrahep:	0.5	0.8	3.2	13.0	17.4	26.8	27.4	10.9	100.0%	65,077
Liver	0.6	0.8	3.3	14.2	17.7	27.0	26.5	9.9	100.0%	51,470
Intrahep bile duct	0.0	0.7	2.8	8.6	16.1	26.4	30.9	14.6	100.0%	13,607
Gallbladder	0.0	0.1	1.9	7.2	14.1	27.1	33.1	16.5	100.0%	9,888
Other biliary	0.0	0.2	1.7	5.4	11.3	24.0	35.2	22.1	100.0%	7,882
Pancreas	0.0	0.2	2.0	8.0	16.2	27.9	31.5	14.3	100.0%	146,812
Retroperitoneum	0.5	2.3	4.8	9.7	17.5	24.9	28.8	11.6	100.0%	1,200
Peritoneum, omentum & mesentery	0.1	0.7	2.4	7.9	20.2	33.4	28.6	6.8	100.0%	2,929
Other digestive system	0.0	0.5	1.9	6.3	12.4	22.8	31.8	24.3	100.0%	4,287
Respiratory System:	0.0	0.1	1.8	7.7	19.3	33.4	29.4	8.2	100.0%	799,882
Nose, nasal cavity & middle ear	0.5	1.8	6.8	13.3	17.7	22.3	24.3	13.5	100.0%	2,292
Larynx	0.0	0.1	2.0	11.1	23.6	31.4	24.6	7.1	100.0%	19,061
Lung & bronchus	0.0	0.1	1.8	7.6	19.2	33.5	29.5	8.2	100.0%	775,558
Lung & bronchus (Male)	0.0	0.1	1.6	7.8	20.0	34.5	28.8	7.1	100.0%	451,690
Lung & bronchus (Female)	0.0	0.1	1.9	7.3	18.2	32.1	30.5	9.8	100.0%	323,868
Pleura	0.2	0.0	1.5	4.9	14.6	30.8	36.9	11.1	100.0%	1,625
Trachea & other respiratory organs	1.7	5.1	6.5	11.7	16.3	25.6	24.1	9.0	100.0%	1,346
Bones & joints	15.2	13.6	7.0	9.0	11.0	14.9	18.6	10.7	100.0%	6,166
Soft tissue (incl heart)	4.0	6.7	8.4	13.5	16.2	20.7	21.2	9.3	100.0%	18,606
Skin (ex basal & squam):	0.1	2.5	7.0	13.8	16.8	22.4	23.8	13.5	100.0%	48,786
Melanoma of the skin	0.1	3.1	8.5	15.5	17.5	22.5	22.5	10.3	100.0%	37,121
Other non-epithelial skin	0.0	0.6	2.3	8.4	14.7	22.2	28.1	23.6	100.0%	11,665
Breast (Female)	0.0	1.1	6.8	15.3	18.1	21.4	23.0	14.3	100.0%	207,660

Source: NCHS public use data file for the total US.

Table I-12 - continued

AGE DISTRIBUTION (%) OF DEATHS BY SITE, 1998-2002

All Races, Both Sexes

Site	Age								All Ages	Cases
	<20	20-34	35-44	45-54	55-64	65-74	75-84	85+		
Female Genital System:	0.0	1.5	5.2	11.9	17.1	24.4	26.8	13.0	100.0%	131,787
Cervix uteri	0.0	5.8	17.1	22.4	17.6	15.8	13.9	7.5	100.0%	20,788
Corpus uteri	0.0	0.3	1.7	6.6	17.0	29.5	30.6	14.3	100.0%	15,790
Uterus, NOS	0.0	0.5	2.4	8.6	15.8	25.5	29.7	17.5	100.0%	17,320
Ovary	0.1	0.8	3.4	11.3	17.9	25.9	28.7	11.9	100.0%	70,173
Vagina	0.0	0.6	3.8	10.2	11.7	20.8	27.8	25.1	100.0%	1,997
Vulva	0.0	0.5	2.7	5.3	8.7	17.9	33.9	30.9	100.0%	3,803
Other female genital system	0.0	2.1	3.1	10.4	18.1	25.7	28.2	12.3	100.0%	1,916
Male Genital System:	0.0	0.4	0.5	1.5	6.4	21.9	41.7	27.5	100.0%	159,208
Prostate	0.0	0.0	0.1	1.2	6.3	22.1	42.3	27.9	100.0%	156,174
Testis	2.1	33.5	28.8	15.7	7.5	5.8	4.6	1.9	100.0%	1,814
Penis	0.0	0.7	4.7	11.3	18.4	25.1	26.2	13.5	100.0%	1,019
Other male genital system	0.0	4.0	6.0	7.5	10.4	18.4	33.3	20.4	100.0%	201
Urinary System:	0.3	0.3	1.9	7.1	14.5	25.5	32.3	18.2	100.0%	122,131
Urinary bladder	0.0	0.1	0.9	3.8	10.3	23.8	36.8	24.3	100.0%	60,521
Kidney & renal pelvis	0.5	0.5	2.9	10.6	19.0	27.3	27.4	11.8	100.0%	58,579
Ureter	0.0	0.1	0.4	3.8	10.2	28.3	37.8	19.3	100.0%	1,563
Other urinary system	0.0	0.2	2.2	7.0	11.9	23.8	35.7	19.3	100.0%	1,468
Eye & Orbit	5.1	1.5	4.9	10.7	18.1	21.0	25.0	13.8	100.0%	1,207
Brain & Nervous System:	4.3	4.2	8.3	15.2	19.2	23.9	19.5	5.5	100.0%	63,525
Endocrine System:	8.4	2.8	5.1	10.2	15.2	22.2	24.8	11.2	100.0%	10,981
Thyroid	0.2	1.0	3.0	8.1	16.0	24.5	31.5	15.7	100.0%	6,472
Other endocrine & thymus	20.3	5.4	8.3	13.2	14.1	18.8	15.1	4.8	100.0%	4,509
Lymphoma:	0.6	2.6	4.0	7.9	13.7	24.5	32.2	14.5	100.0%	119,856
Hodgkin lymphoma	2.5	16.2	12.2	12.6	11.9	18.1	19.2	7.4	100.0%	6,676
Non-Hodgkin lymphoma	0.5	1.8	3.5	7.7	13.9	24.9	32.9	14.9	100.0%	113,180
Myeloma	0.0	0.1	1.4	6.3	14.8	28.9	34.5	13.9	100.0%	53,100
Leukemia:	3.3	3.5	3.9	6.7	11.8	23.4	31.1	16.4	100.0%	106,050
Lymphocytic:	5.1	3.7	2.7	5.0	10.2	21.3	30.8	21.3	100.0%	30,785
Acute lymphocytic	22.2	15.7	9.6	10.7	11.1	12.9	12.4	5.6	100.0%	7,057
Chronic lymphocytic	0.0	0.1	0.6	3.1	9.8	24.0	36.2	26.2	100.0%	21,777
Other lymphocytic	0.8	0.4	1.5	4.9	11.0	21.8	36.1	23.5	100.0%	1,951
Myeloid & Monocytic:	2.5	3.8	5.1	8.6	13.7	25.2	29.7	11.4	100.0%	48,940
Acute myeloid	2.9	3.7	4.8	8.4	13.9	26.1	29.8	10.3	100.0%	36,593
Chronic myeloid	1.1	5.0	7.6	11.3	14.2	21.9	26.2	12.7	100.0%	8,910
Acute monocytic	3.7	2.4	4.3	5.3	11.3	22.3	31.8	18.9	100.0%	628
Other myeloid & monocytic	1.4	1.0	1.6	3.3	10.0	24.8	38.9	19.0	100.0%	2,809
Other:	2.6	2.6	2.9	5.3	10.0	22.4	34.3	20.0	100.0%	26,325
Other acute	1.6	2.9	3.3	5.7	10.6	24.4	35.2	16.3	100.0%	12,498
Aleukemic, subleuk & NOS	3.4	2.3	2.6	4.9	9.5	20.6	33.4	23.4	100.0%	13,827
Ill-defined & unspecified	0.2	0.8	2.7	8.1	15.3	25.7	30.8	16.4	100.0%	211,464

Source: NCHS public use data file for the total US.

Table I-13
MEDIAN AGE OF CANCER PATIENTS AT DEATH^a, 1998-2002
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	72.0	72.0	73.0	73.0	72.0	74.0	69.0	68.0	69.0
Oral Cavity & Pharynx:	68.0	66.0	74.0	70.0	67.0	75.0	61.0	60.0	65.0
Lip	76.0	74.0	83.0	77.0	74.0	84.0	-	-	-
Tongue	67.0	64.0	73.0	68.0	65.0	74.0	60.0	59.0	62.5
Salivary gland	74.0	73.0	75.0	74.0	73.0	76.0	63.0	63.0	65.0
Floor of mouth	66.0	63.0	72.0	67.0	65.0	73.0	59.0	58.0	67.0
Gum & other oral cavity	73.0	68.0	79.0	74.0	69.0	80.0	64.0	62.0	70.0
Nasopharynx	62.0	60.0	66.0	66.0	63.0	70.0	56.0	54.0	60.0
Tonsil	63.0	61.0	69.0	64.0	62.0	71.0	59.0	59.0	59.0
Oropharynx	67.0	65.0	73.0	69.0	67.0	74.0	59.0	58.0	64.5
Hypopharynx	66.0	66.0	70.0	68.0	67.0	71.0	60.5	60.0	64.0
Other oral cavity & pharynx	69.0	67.0	72.0	70.0	69.0	73.0	63.0	62.0	66.0
Digestive System:	73.0	71.0	76.0	74.0	72.0	77.0	69.0	67.0	72.0
Esophagus	70.0	69.0	74.0	71.0	69.0	76.0	65.0	64.0	68.0
Stomach	74.0	72.0	76.0	74.0	73.0	77.0	71.0	69.0	75.0
Small intestine	71.0	70.0	73.0	72.0	71.0	74.0	65.0	63.0	67.0
Colon & Rectum	75.0	73.0	77.0	75.0	73.0	78.0	71.0	69.0	73.0
Anus, anal canal & anorectum	67.0	63.0	69.0	67.0	64.0	70.0	60.0	54.0	67.0
Liver & Intrahep:	71.0	68.0	75.0	72.0	70.0	75.0	64.0	60.0	70.0
Liver	70.0	67.0	75.0	71.0	69.0	76.0	63.0	59.0	70.0
Intrahep bile duct	73.0	72.0	75.0	74.0	72.0	75.0	69.0	68.0	70.0
Gallbladder	74.0	74.0	75.0	75.0	74.0	75.0	71.0	70.0	71.0
Other biliary	77.0	75.0	78.0	77.0	75.0	79.0	72.0	71.0	73.0
Pancreas	73.0	71.0	75.0	74.0	71.0	76.0	70.0	67.0	73.0
Retroperitoneum	71.0	70.0	73.0	72.0	70.0	73.0	64.0	63.5	64.0
Peritoneum, omentum & mesentery	71.0	68.0	71.0	71.0	69.0	71.0	67.0	58.5	68.5
Other digestive system	77.0	74.0	80.0	77.0	74.0	80.0	71.0	69.0	74.0
Respiratory System:	71.0	71.0	72.0	72.0	71.0	72.0	67.0	67.0	68.0
Nose, nasal cavity & middle ear	70.0	66.0	74.0	71.0	68.0	75.0	60.5	59.0	66.0
Larynx	69.0	68.0	70.0	70.0	70.0	71.0	64.0	63.0	66.0
Lung & bronchus	71.0	71.0	72.0	72.0	71.0	72.0	68.0	67.0	68.0
Pleura	74.0	74.0	75.5	74.0	74.0	76.0	70.0	69.5	-
Trachea & other respiratory organs	68.0	65.0	72.0	69.0	66.0	72.5	63.5	62.0	65.0
Bones & joints	59.0	55.0	65.5	61.0	57.0	68.0	48.0	46.0	55.5
Soft tissue (incl heart)	65.0	64.0	67.0	67.0	65.0	68.0	57.0	53.0	59.0
Skin (ex basal & squam):	69.0	68.0	71.0	69.0	69.0	71.0	65.0	62.0	71.0
Melanoma of the skin	67.0	67.0	68.0	67.0	67.0	68.0	71.0	66.0	73.0
Other non-epithelial skin	75.0	73.0	80.0	76.0	74.0	81.0	62.0	60.0	67.0
Breast	69.0	71.0	69.0	70.0	72.0	70.0	61.0	67.0	61.0

^a NCHS public use data file for the total US.
 - Statistic could not be calculated. Less than 25 deaths occurred during the time interval.

Table I-13 - continued
MEDIAN AGE OF CANCER PATIENTS AT DEATH^a, 1998-2002
 By Primary Cancer Site, Race and Sex

Site	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	71.0	-	71.0	71.0	-	71.0	67.0	-	67.0
Cervix uteri	57.0	-	57.0	57.0	-	57.0	58.0	-	58.0
Corpus uteri	73.0	-	73.0	73.0	-	73.0	71.0	-	71.0
Uterus, NOS	74.0	-	74.0	75.0	-	75.0	70.0	-	70.0
Ovary	71.0	-	71.0	72.0	-	72.0	68.0	-	68.0
Vagina	76.0	-	76.0	77.0	-	77.0	71.0	-	71.0
Vulva	79.0	-	79.0	80.0	-	80.0	72.0	-	72.0
Other female genital system	71.0	-	71.0	72.0	-	72.0	66.5	-	66.5
Male Genital System:	79.0	79.0	-	80.0	80.0	-	77.0	77.0	-
Prostate	79.0	79.0	-	80.0	80.0	-	77.0	77.0	-
Testis	39.5	39.5	-	40.0	40.0	-	39.0	39.0	-
Penis	70.0	70.0	-	71.0	71.0	-	67.0	67.0	-
Other male genital system	75.0	75.0	-	76.0	76.0	-	70.0	70.0	-
Urinary System:	75.0	74.0	77.0	75.0	74.0	77.0	71.0	69.0	74.0
Urinary bladder	78.0	77.0	80.0	78.0	77.0	80.0	75.0	74.0	77.0
Kidney & renal pelvis	71.0	69.0	74.0	71.0	70.0	74.0	67.0	65.0	70.0
Ureter	76.0	76.0	77.0	76.0	75.5	77.0	74.0	-	73.5
Other urinary system	76.0	75.0	77.0	77.0	75.0	79.0	65.0	67.0	64.0
Eye & Orbit	70.0	68.0	73.0	71.0	68.0	73.0	47.0	-	48.5
Brain & Nervous System:	64.0	62.0	66.0	64.0	63.0	67.0	58.0	56.0	60.0
Endocrine System:	69.0	65.0	72.0	70.0	66.0	72.0	61.0	56.0	65.0
Thyroid	74.0	70.0	76.0	74.0	71.0	76.0	69.0	64.0	72.0
Other endocrine & thymus	56.0	55.0	58.0	58.0	57.0	60.0	47.0	45.0	49.0
Lymphoma:	73.0	71.0	76.0	74.0	72.0	76.0	63.0	60.0	67.0
Hodgkin lymphoma	60.0	58.0	64.0	63.0	60.0	66.0	43.5	44.5	41.0
Non-Hodgkin lymphoma	74.0	72.0	76.0	74.0	72.0	76.0	65.0	62.0	68.0
Myeloma	74.0	73.0	75.0	75.0	74.0	76.0	71.0	70.0	72.0
Leukemia:	74.0	72.0	75.0	74.0	73.0	76.0	67.0	65.0	69.0
Lymphocytic:	75.0	73.0	78.0	76.0	74.0	79.0	69.0	67.0	72.0
Acute lymphocytic	47.0	42.0	52.0	48.0	44.0	54.0	35.0	31.0	41.0
Chronic lymphocytic	78.0	76.0	81.0	78.0	76.0	82.0	73.0	71.0	76.0
Other lymphocytic	77.0	76.0	80.0	78.0	76.0	80.0	73.0	70.0	76.0
Myeloid & Monocytic:	72.0	71.0	72.0	72.0	72.0	73.0	63.0	62.0	65.0
Acute myeloid	71.0	71.0	72.0	72.0	72.0	72.0	64.0	64.0	65.0
Chronic myeloid	70.0	68.0	72.0	72.0	70.0	73.0	59.0	54.0	64.0
Acute monocytic	75.0	74.0	76.0	75.0	74.5	77.0	54.0	-	-
Other myeloid & monocytic	76.0	76.0	78.0	77.0	76.0	78.0	73.0	71.0	75.0
Other:	76.0	74.0	78.0	76.0	75.0	78.0	71.0	69.0	73.0
Other acute	75.0	74.0	76.0	75.0	74.0	77.0	70.0	68.0	71.0
Aleukemic, subleuk & NOS	77.0	75.0	79.0	77.0	76.0	80.0	71.0	69.0	74.0
Ill-defined & unspecified	74.0	72.0	76.0	74.0	73.0	76.0	69.0	67.0	71.0

^a NCHS public use data file for the total US.
 - Statistic could not be calculated. Less than 25 deaths occurred during the time interval.

Table I-14

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site, Race and Sex

13 SEER Areas, 2000-2002

Site	All Races		Whites		Blacks	
	Males	Females	Males	Females	Males	Females
All Sites	45.67	38.09	46.11	39.45	42.50	31.88
Invasive and In Situ	46.91	41.44	47.48	42.99	42.79	33.99
Oral cavity and Pharynx	1.38	0.68	1.40	0.70	1.29	0.50
Esophagus	0.76	0.25	0.78	0.24	0.77	0.34
Stomach	1.22	0.75	1.06	0.61	1.27	0.97
Colon and Rectum	5.84	5.51	5.84	5.48	4.99	5.41
Invasive and In Situ	6.13	5.74	6.13	5.70	5.25	5.66
Liver and Intrahepatic bile duct	0.89	0.43	0.71	0.36	0.95	0.35
Pancreas	1.26	1.27	1.28	1.23	1.16	1.46
Larynx	0.62	0.14	0.62	0.15	0.85	0.19
Invasive and In Situ	0.66	0.15	0.67	0.16	0.88	0.20
Lung and Bronchus	7.58	5.72	7.59	6.01	8.08	5.24
Melanoma of skin	1.94	1.30	2.33	1.59	0.08	0.06
Invasive and In Situ	3.13	2.14	3.73	2.59	0.10	0.09
Breast	0.12	13.22	0.12	14.04	0.16	9.98
Invasive and In Situ	0.13	15.81	0.14	16.71	0.17	11.97
Cervix uteri	-	0.74	-	0.71	-	0.87
Corpus and Uterus, NOS	-	2.61	-	2.79	-	1.87
Invasive and In Situ	-	2.64	-	2.83	-	1.89
Ovary	-	1.48	-	1.59	-	0.92
Prostate	17.93	-	17.73	-	20.66	-
Testis	0.36	-	0.43	-	0.10	-
Urinary bladder(Invasive and In Situ)	3.58	1.14	3.99	1.24	1.39	0.80
Kidney and Renal pelvis	1.56	0.91	1.64	0.94	1.45	0.91
Brain and Other nervous system	0.65	0.50	0.74	0.57	0.32	0.28
Thyroid	0.35	0.97	0.38	1.02	0.17	0.53
Hodgkin lymphoma	0.24	0.19	0.25	0.21	0.21	0.15
Non-Hodgkin lymphoma	2.18	1.82	2.32	1.94	1.25	1.06
Multiple myeloma	0.70	0.55	0.68	0.51	0.94	0.93
Leukemia	1.50	1.07	1.61	1.14	0.87	0.79
Acute Lymphocytic Leukemia	0.12	0.11	0.14	0.12	0.04	0.06
Chronic Lymphocytic Leukemia	0.53	0.33	0.59	0.35	0.26	0.20
Acute Myeloid Leukemia	0.46	0.35	0.48	0.37	0.29	0.30
Chronic Myeloid Leukemia	0.19	0.14	0.19	0.14	0.13	0.11
Kaposi Sarcoma	0.12	0.02	0.10	0.02	0.23	0.02
Mesothelioma	0.19	0.05	0.22	0.05	0.06	0.02

Devcan Version 6.0, April 2005, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia).

Note: Invasive cancer only unless specified otherwise.

Table I-15

Lifetime Risk (Percent) of Dying from Cancer by Site, Race and Sex

Total U.S., 2000-2002

Site	All Races		Whites		Blacks	
	Males	Females	Males	Females	Males	Females
All Sites	23.56	19.93	23.62	20.16	24.21	19.43
Oral cavity and Pharynx	0.38	0.19	0.37	0.19	0.50	0.17
Esophagus	0.74	0.22	0.74	0.21	0.81	0.31
Stomach	0.59	0.40	0.53	0.35	0.89	0.67
Colon and Rectum	2.36	2.23	2.36	2.20	2.46	2.51
Liver and Intrahepatic bile duct	0.65	0.37	0.61	0.35	0.69	0.38
Pancreas	1.17	1.17	1.18	1.16	1.13	1.33
Larynx	0.23	0.06	0.22	0.06	0.38	0.09
Lung and Bronchus	7.25	4.92	7.33	5.12	7.29	3.97
Melanoma of skin	0.35	0.20	0.40	0.22	0.03	0.04
Breast	0.03	2.96	0.03	2.96	0.05	3.25
Cervix uteri	-	0.26	-	0.23	-	0.46
Corpus and Uterus, NOS	-	0.51	-	0.48	-	0.75
Ovary	-	1.05	-	1.10	-	0.74
Prostate	2.97	-	2.78	-	4.71	-
Testis	0.02	-	0.02	-	0.01	-
Urinary bladder	0.75	0.32	0.80	0.32	0.39	0.33
Kidney and Renal pelvis	0.59	0.34	0.61	0.35	0.45	0.28
Brain and Other nervous system	0.49	0.39	0.53	0.42	0.23	0.21
Thyroid	0.04	0.06	0.05	0.06	0.03	0.06
Hodgkin lymphoma	0.05	0.04	0.05	0.04	0.04	0.03
Non-Hodgkin lymphoma	0.94	0.81	1.00	0.86	0.50	0.43
Multiple myeloma	0.46	0.40	0.44	0.38	0.63	0.67
Leukemia	0.97	0.72	1.02	0.75	0.64	0.54
Acute Lymphocytic Leukemia	0.05	0.04	0.05	0.04	0.03	0.02
Chronic Lymphocytic Leukemia	0.23	0.15	0.24	0.16	0.16	0.11
Acute Myeloid Leukemia	0.33	0.25	0.35	0.26	0.19	0.17
Chronic Myeloid Leukemia	0.07	0.05	0.07	0.05	0.06	0.05

Devcan Version 6.0, April 2005, National Cancer Institute (<http://srab.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

Table I-16
 US AND SEER DEATH RATES BY PRIMARY CANCER SITE AND RACE/ETHNICITY, 1992-2002

Site		Total United States ^a							SEER 11 Areas, Alaska and Rural Georgia ^a						
		Total	White	Black	AI/AN ^b	API ^c	Hisp ^d	W-NHisp ^d	Total	White	Black	AI/AN ^b	API ^c	Hisp ^d	W-NHisp ^d
All Sites	Both Sexes	204.0	200.8	259.3	135.3	125.1	137.4	204.0	189.9	190.3	249.2	143.1	136.0	137.4	195.3
	Male	258.6	252.5	360.5	165.5	155.7	175.7	256.7	234.7	233.3	334.3	171.5	171.2	172.4	238.3
	Female	169.2	167.9	199.2	115.2	102.3	112.1	170.2	161.4	163.5	197.8	123.4	109.1	115.5	168.4
Oral Cavity & Pharynx	Both Sexes	3.0	2.8	4.7	2.3	2.5	1.9	2.9	2.9	2.7	4.1	3.3	2.9	1.7	2.9
	Male	4.5	4.2	8.2	3.6	3.8	3.2	4.3	4.3	4.0	7.0	5.3	4.4	2.9	4.1
	Female	1.7	1.7	2.1	1.3	1.5	0.9	1.7	1.8	1.7	2.0	1.8	1.7	0.8	1.9
Esophagus	Both Sexes	4.3	4.1	7.3	2.7	2.1	2.4	4.1	4.1	4.0	6.5	3.6	2.4	2.3	4.2
	Male	7.6	7.2	12.9	4.8	3.6	4.5	7.3	7.0	7.0	10.8	6.3	4.2	4.4	7.2
	Female	1.8	1.6	3.5	1.1	0.9	0.9	1.6	1.8	1.7	3.4	1.5	0.9	0.8	1.8
Stomach	Both Sexes	4.9	4.4	9.6	5.5	9.7	7.4	4.0	5.6	4.7	9.1	8.0	10.7	8.5	4.1
	Male	7.1	6.3	14.1	7.4	12.6	10.0	5.9	8.0	6.8	13.1	11.1	14.2	11.6	6.0
	Female	3.4	3.0	6.7	4.2	7.5	5.5	2.7	3.9	3.3	6.3	5.7	8.1	6.4	2.7
Colon & Rectum	Both Sexes	21.6	21.1	28.6	13.8	13.5	14.2	21.2	19.9	19.7	27.5	15.7	15.1	14.0	20.0
	Male	26.3	25.8	34.8	16.1	16.4	17.9	25.9	24.1	23.9	33.0	17.2	18.6	18.0	24.2
	Female	18.3	17.8	24.7	12.1	11.3	11.5	17.8	17.0	16.7	24.1	14.4	12.4	11.2	17.0
Liver & Intrahepatic Bile Duct	Both Sexes	4.4	4.1	6.0	5.6	10.8	7.2	3.9	5.0	4.2	6.2	7.0	10.9	7.2	3.8
	Male	6.5	5.9	9.2	7.6	15.9	10.2	5.6	7.3	6.0	9.5	9.0	16.1	10.3	5.5
	Female	2.9	2.7	3.7	4.1	6.5	4.8	2.6	3.2	2.7	3.7	5.6	6.6	4.9	2.5
Pancreas	Both Sexes	10.6	10.3	14.4	6.2	7.5	8.4	10.3	10.4	10.2	14.6	7.2	8.0	8.5	10.3
	Male	12.3	12.0	16.4	6.3	8.4	9.4	12.0	11.8	11.7	15.9	7.6	9.2	9.1	11.9
	Female	9.2	8.9	12.9	6.1	6.7	7.6	8.9	9.2	9.0	13.3	6.9	7.1	8.0	9.1
Larynx	Both Sexes	1.5	1.3	2.9	1.1	0.5	1.1	1.3	1.3	1.2	2.7	1.1	0.5	0.9	1.2
	Male	2.7	2.4	5.7	1.9	0.9	2.2	2.4	2.3	2.2	5.1	2.2	0.9	1.8	2.2
	Female	0.5	0.5	0.9	0.5	0.1	0.2	0.5	0.5	0.5	0.9	0.2	0.1	0.2	0.5
Lung & Bronchus	Both Sexes	57.1	56.9	66.9	36.3	28.6	25.5	59.3	49.0	49.6	65.0	32.3	31.5	23.7	52.6
	Male	80.8	79.3	109.1	50.0	41.1	40.4	82.5	66.3	65.7	100.3	44.7	45.7	35.9	68.7
	Female	40.3	41.1	39.3	26.4	19.0	14.9	42.8	36.9	38.4	41.4	23.0	20.4	15.3	41.2
Melanoma of the Skin	Both Sexes	2.7	3.0	0.5	0.7	0.4	0.8	3.2	2.4	2.8	0.4	0.5	0.4	0.8	3.2
	Male	3.9	4.4	0.5	0.9	0.5	1.1	4.6	3.4	4.1	0.4	0.7	0.6	0.9	4.5
	Female	1.8	2.0	0.5	0.5	0.3	0.6	2.1	1.6	1.9	0.4	0.4	0.3	0.7	2.1
Breast	Female	28.5	28.0	36.2	14.4	12.9	17.7	28.3	27.5	27.9	36.2	15.9	14.8	17.4	29.0

^a NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b American Indian/Alaskan Native.

^c Asian/Pacific Islander.

^d Mortality data for Hispanics (Hisp) and White Non-Hispanics (W-NHisp) do not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

- Statistic could not be calculated.

Table I-16 - continued
 US AND SEER DEATH RATES BY PRIMARY CANCER SITE AND RACE/ETHNICITY, 1992-2002

Site		Total United States ^a							SEER 11 Areas, Alaska and Rural Georgia ^a						
		Total	White	Black	AI/AN ^b	API ^c	Hispanic ^d	W-NHispanic ^d	Total	White	Black	AI/AN ^b	API ^c	Hispanic ^d	W-NHispanic ^d
Cervix	Female	3.0	2.7	6.2	3.2	2.9	3.8	2.6	2.7	2.4	4.8	2.8	2.7	3.9	2.2
Corpus & Uterus, NOS	Female	4.1	3.9	7.0	2.6	2.2	3.2	3.9	4.1	4.0	6.3	2.6	2.5	3.1	4.1
Ovary	Female	9.0	9.3	7.6	5.1	4.8	6.2	9.5	9.0	9.6	7.1	6.0	5.0	6.5	10.1
Prostate	Male	33.9	31.2	73.7	21.5	14.1	24.7	31.4	32.0	31.1	67.0	17.4	15.3	24.9	31.8
Testis	Male	0.3	0.3	0.2	0.2	0.1	0.3	0.3	0.3	0.3	0.2	0.3	0.1	0.3	0.3
Urinary Bladder	Both Sexes	4.4	4.5	4.0	1.6	1.9	2.4	4.5	4.1	4.3	4.0	1.7	2.0	2.3	4.4
	Male	7.7	8.0	5.9	2.5	2.9	4.2	8.1	7.0	7.6	5.9	2.6	3.1	3.6	7.8
	Female	2.3	2.3	3.0	1.1	1.1	1.3	2.3	2.2	2.2	2.9	1.0	1.1	1.4	2.3
Kidney & Renal Pelvis	Both Sexes	4.2	4.3	4.2	4.9	1.9	3.8	4.3	3.9	4.0	4.0	5.4	2.1	3.7	4.1
	Male	6.2	6.2	6.2	6.8	2.7	5.5	6.3	5.6	5.9	5.9	7.7	3.1	5.4	5.9
	Female	2.8	2.9	2.8	3.4	1.2	2.4	2.9	2.6	2.7	2.7	3.8	1.3	2.5	2.7
Brain & Nervous System	Both Sexes	4.7	5.0	2.7	2.0	1.9	2.9	5.2	4.5	5.0	2.8	2.0	2.2	3.0	5.3
	Male	5.7	6.1	3.3	2.4	2.4	3.5	6.3	5.6	6.1	3.4	2.6	2.7	3.5	6.6
	Female	3.8	4.1	2.3	1.6	1.6	2.5	4.2	3.6	4.0	2.4	1.6	1.7	2.6	4.3
Thyroid	Both Sexes	0.5	0.5	0.5	0.3	0.7	0.6	0.4	0.5	0.5	0.4	0.4	0.7	0.8	0.4
	Male	0.4	0.4	0.3	0.2	0.5	0.5	0.4	0.4	0.4	0.3	0.4	0.6	0.5	0.4
	Female	0.5	0.5	0.5	0.4	0.8	0.7	0.4	0.5	0.5	0.4	0.5	0.9	0.9	0.4
Hodgkin Lymphoma	Both Sexes	0.5	0.5	0.5	0.2	0.2	0.5	0.5	0.5	0.5	0.5	0.1	0.2	0.6	0.5
	Male	0.6	0.7	0.6	0.2	0.3	0.7	0.7	0.6	0.7	0.7	0.1	0.2	0.8	0.7
	Female	0.4	0.4	0.4	0.2	0.1	0.4	0.4	0.4	0.4	0.4	0.1	0.1	0.4	0.4
Non-Hodgkin Lymphoma	Both Sexes	8.4	8.7	5.7	4.4	5.2	6.5	8.8	8.1	8.6	5.6	4.1	5.7	6.4	8.9
	Male	10.4	10.8	7.4	5.1	6.6	8.0	10.9	10.1	10.7	7.0	5.3	7.4	8.1	11.0
	Female	6.8	7.1	4.5	3.8	4.1	5.3	7.2	6.6	7.1	4.7	3.1	4.3	5.2	7.2
Myeloma	Both Sexes	3.9	3.6	7.5	2.9	1.8	3.2	3.6	3.8	3.7	7.5	3.2	1.9	3.4	3.8
	Male	4.8	4.5	9.1	3.3	2.2	3.8	4.5	4.7	4.7	8.6	3.9	2.2	4.2	4.8
	Female	3.2	2.9	6.5	2.7	1.6	2.7	2.9	3.2	3.0	6.9	2.7	1.6	2.9	3.1
Leukemia	Both Sexes	7.7	7.9	7.0	4.1	4.3	5.3	8.0	7.5	7.8	7.1	3.5	4.8	5.4	8.0
	Male	10.4	10.6	9.3	5.1	5.4	6.7	10.8	9.9	10.5	9.2	4.5	6.1	6.6	10.8
	Female	5.9	6.0	5.5	3.4	3.4	4.3	6.1	5.8	6.0	5.7	2.8	3.7	4.5	6.1

^a NCHS public use data file for the total US. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b American Indian/Alaskan Native.

^c Asian/Pacific Islander.

^d Mortality data for Hispanics (Hispanic) and White Non-Hispanics (W-NHispanic) do not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont. Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

- Statistic could not be calculated.

Table I-17
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2002^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			27-year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 27 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 27 Years ^d
All Sites	3,867,003	3,941,332	4,238,091	9,430,525	9,606,482
Male	1,957,153	1,983,555	2,125,418	4,356,626	4,406,570
Female	1,909,850	1,957,777	2,112,673	5,073,899	5,199,912
Oral Cavity & Pharynx	82,465	93,657	96,502	209,742	228,987
Male	54,587	61,351	63,058	134,000	144,924
Female	27,878	32,306	33,444	75,742	84,063
Esophagus	16,212	19,256	19,256	23,139	27,099
Male	12,545	14,664	14,664	17,520	20,164
Female	3,667	4,592	4,592	5,619	6,935
Stomach	29,294	33,978	34,082	56,255	63,243
Male	17,931	20,805	20,838	32,491	36,516
Female	11,363	13,173	13,244	23,764	26,727
Colon & Rectum	409,449	468,805	476,603	990,228	1,095,712
Male	205,302	235,516	238,820	482,617	530,469
Female	204,147	233,289	237,783	507,611	565,243
Liver & Intrahep	11,552	13,206	13,217	15,152	17,046
Male	7,508	8,594	8,605	9,437	10,650
Female	4,044	4,612	4,612	5,715	6,396
Pancreas	19,344	22,700	22,700	25,555	29,428
Male	9,438	11,214	11,214	12,274	14,270
Female	9,906	11,486	11,486	13,281	15,158
Larynx	32,997	37,965	38,182	91,754	100,304
Male	26,181	30,101	30,259	73,344	79,883
Female	6,816	7,864	7,923	18,410	20,421
Lung & Bronchus	202,674	246,254	250,392	335,447	395,971
Male	100,886	123,709	125,599	165,547	194,890
Female	101,788	122,545	124,793	169,900	201,081
Melanoma of the Skin	202,999	223,960	229,859	578,663	615,944
Male	107,851	120,689	124,506	286,244	307,023
Female	95,148	103,271	105,353	292,419	308,921
Breast					
Female	810,067	867,306	903,843	2,147,690	2,277,797
Cervix					
Female	44,613	46,898	46,925	179,134	184,371
Corpus & Uterus					
Female	142,978	160,405	160,468	485,208	522,668
Ovary					
Female	54,659	62,754	62,758	142,293	158,788

^a US 2002 cancer prevalence counts are based on 2002 cancer prevalence proportions from the SEER 9 registries and 1/1/2002 US population estimates based on the average of 2001 and 2002 population estimates from the US Bureau of the Census.

^{bcd} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 27 years (1975-2001); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1997-2001). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1997; Melanoma in 1998.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 27-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred 20 years ago.
 In method (d) the 1981 melanoma is counted for the melanoma and all sites 27-year limited duration prevalence. The 1997 breast cancer is counted for the breast 5-year and 27-year limited duration prevalence.
 In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1998 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table I-17 - continued
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2002^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

Site/Sex	5-Year Limited Duration			27-year Limited Duration	
	1st Invasive Tumor Ever ^c	1st Per Site in Previous 27 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 27 Years ^d
Prostate					
Male	892,138	960,511	960,545	1,826,301	1,949,727
Testis					
Male	37,578	38,062	38,571	144,174	145,865
Urinary Bladder					
Male	184,483	221,675	223,454	471,823	535,752
Female	138,422	166,292	167,816	349,628	395,599
Female	46,061	55,383	55,638	122,195	140,153
Kidney & Renal Pelvis					
Male	89,323	107,038	107,849	207,723	237,885
Female	53,720	65,276	65,792	123,059	141,698
Female	35,603	41,762	42,057	84,664	96,187
Brain & Nervous System					
Male	35,503	37,509	37,641	91,881	94,763
Female	19,416	20,452	20,517	49,872	51,377
Female	16,087	17,057	17,124	42,009	43,386
Thyroid					
Male	88,240	94,590	94,806	279,685	292,893
Female	20,450	22,504	22,553	63,721	67,300
Female	67,790	72,086	72,253	215,964	225,593
Hodgkin Lymphoma					
Male	33,241	34,605	34,627	125,113	127,804
Female	17,560	18,312	18,312	65,330	66,779
Female	15,681	16,293	16,315	59,783	61,025
Non-Hodgkin Lymphoma					
Male	154,821	175,583	176,195	332,657	365,300
Female	81,328	92,287	92,613	172,701	188,781
Female	73,493	83,296	83,582	159,956	176,519
Myeloma					
Male	34,833	39,821	39,844	49,931	56,104
Female	18,832	21,683	21,706	27,208	30,707
Female	16,001	18,138	18,138	22,723	25,397
Leukemia					
Male	80,095	89,786	89,845	183,579	198,257
Female	46,350	52,154	52,201	103,787	112,084
Female	33,745	37,632	37,644	79,792	86,173
Acute Lymphocytic Leuk					
Male	13,598	13,731	13,731	44,730	44,955
Female	7,581	7,624	7,624	24,523	24,604
Female	6,017	6,107	6,107	20,207	20,351
Childhood (0-19)					
Male	55,930	56,015	56,307	215,915	216,360
Female	29,328	29,380	29,523	110,475	110,683
Female	26,602	26,635	26,784	105,440	105,677
Kaposi's Sarcoma					
Male	7,140	7,674	7,708	19,711	20,644
Female	6,545	7,024	7,058	18,332	19,151
Female	595	650	650	1,379	1,493
Mesothelioma					
Male	3,065	3,626	3,626	4,422	5,077
Female	2,144	2,643	2,643	2,686	3,256
Female	921	983	983	1,736	1,821

^a US 2002 cancer prevalence counts are based on 2002 cancer prevalence proportions from the SEER 9 registries and 1/1/2002 US population estimates based on the average of 2001 and 2002 population estimates from the US Bureau of the Census.

^{bcd} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 27 years (1975-2001); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (1997-2001). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 1997; Melanoma in 1998.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 27-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred 20 years ago. In method (d) the 1981 melanoma is counted for the melanoma and all sites 27-year limited duration prevalence. The 1997 breast cancer is counted for the breast 5-year and 27-year limited duration prevalence. In method (e) the 1997 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 1998 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table I-18
US COMPLETE PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2002^a
BY AGE AT PREVALENCE

Age at Prevalence	Age Specific								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
<u>Site/Sex</u>									
All Sites									
Males	4,503,895	16,687	35,355	62,064	146,126	300,518	580,447	1,013,496	2,349,201
Females	5,642,429	14,040	30,938	66,090	210,795	556,663	970,592	1,154,712	2,638,599
Breast									
Males	11,780	0	11	0	153	502	1,913	3,066	6,135
Females	2,278,269	0	59	1,906	36,453	198,739	446,463	521,249	1,073,401
Colon & Rectum									
Males	505,267	0	80	644	4,721	19,026	56,080	112,718	311,998
Females	546,415	11	63	704	4,461	17,769	47,993	92,415	382,999
Corpus & Uterus, NOS									
Females	571,854	0	56	388	4,101	22,096	67,003	112,603	365,607
Esophagus									
Males	17,651	0	0	40	189	1,112	3,871	5,437	7,002
Females	5,751	0	11	11	71	208	629	1,349	3,471
Larynx									
Males	78,348	0	11	22	274	2,990	11,043	21,374	42,633
Females	19,555	0	0	33	210	1,335	2,433	5,714	9,829
Lung & Bronchus									
Males	174,384	34	77	269	976	6,943	24,344	50,180	91,561
Females	176,295	11	22	321	1,447	7,463	24,410	48,055	94,565
Melanoma of the Skin									
Males	304,097	78	552	4,111	16,149	45,683	69,092	66,751	101,680
Females	325,725	57	684	8,250	30,125	63,878	73,988	57,468	91,275
Non-Hodgkin Lymphoma									
Males	180,337	614	3,030	5,687	11,579	23,291	34,346	39,245	62,544
Females	166,702	307	1,354	2,960	7,638	16,193	27,250	34,245	76,756
Oral Cavity & Pharynx									
Males	147,272	56	468	1,229	3,579	13,645	30,185	36,114	61,995
Females	84,527	96	458	1,280	3,399	7,667	13,677	18,157	39,792
Ovary									
Females	169,875	56	1,014	2,956	7,766	21,466	34,390	36,707	65,519
Prostate									
Males	1,831,929	34	92	97	230	13,222	143,741	449,469	1,225,043
Stomach									
Males	34,258	3	11	107	471	2,113	4,669	8,130	18,753
Females	25,053	11	23	49	547	1,601	2,540	4,566	15,715
Urinary Bladder									
Males	367,550	28	171	623	2,641	13,157	39,326	82,579	229,024
Females	131,649	22	34	300	1,496	4,445	11,884	25,578	87,888
Myeloma									
Males	27,357	0	5	27	457	1,873	5,778	7,631	11,586
Females	23,127	0	11	33	259	1,184	4,161	5,316	12,162

^a US 2002 cancer prevalence counts are based on 2002 cancer prevalence proportions from the SEER 9 registries and 1/1/2002 US population estimates based on the average of 2001 and 2002 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 27 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table I-19
AGE-ADJUSTED RATES AND TRENDS^a FOR THE TOP 15 CANCER SITES^b BY RACE/ETHNICITY

SEER Cancer Incidence^c 1992-2002
Both Sexes

All Races			White			Black		
	Rate	APC		Rate	APC		Rate	APC
All Sites	475.4	-0.6 ^e	All Sites	483.5	-0.4 ^e	All Sites	526.7	-1.0 ^e
Prostate	180.1	-2.0 ^e	Prostate	175.5	-2.1 ^e	Prostate	283.8	-1.9 ^e
Breast (Females)	132.4	0.4	Breast (Females)	138.3	0.5	Breast (Females)	120.2	-0.2
Lung and Bronchus	63.2	-1.3 ^e	Lung and Bronchus	63.7	-1.1 ^e	Lung and Bronchus	81.6	-1.4 ^e
Colon and Rectum	53.9	-0.8 ^e	Colon and Rectum	53.6	-0.9 ^e	Colon and Rectum	62.6	-0.3
Corpus and Uterus, NOS	24.4	-0.2	Corpus and Uterus, NOS	25.9	-0.3	Corpus and Uterus, NOS	18.4	1.8 ^e
Urinary Bladder	20.3	-0.2	Urinary Bladder	22.3	0.0	Pancreas	16.0	-1.9 ^e
Non-Hodgkin Lymphoma	19.2	0.1	Non-Hodgkin Lymphoma	20.2	0.1	Non-Hodgkin Lymphoma	14.4	0.3
Melanoma of the Skin	16.2	2.4 ^e	Melanoma of the Skin	19.2	2.9 ^e	Stomach	13.7	-1.5 ^e
Ovary	14.2	-0.9 ^e	Ovary	15.1	-0.8 ^e	Kidney and Renal Pelvis	13.1	2.3 ^e
Leukemia	12.5	-0.9 ^e	Leukemia	13.2	-0.8 ^e	Oral Cavity and Pharynx	12.6	-2.8 ^e
Pancreas	11.1	-0.3	Kidney and Renal Pelvis	11.4	1.7 ^e	Cervix Uteri	12.6	-3.8 ^e
Kidney and Renal Pelvis	11.1	1.5 ^e	Oral Cavity and Pharynx	11.0	-1.2 ^e	Urinary Bladder	12.5	0.2
Oral Cavity and Pharynx	11.0	-1.5 ^e	Pancreas	10.9	0.0	Myeloma	11.5	-1.3 ^e
Cervix Uteri	9.7	-2.8 ^e	Cervix Uteri	9.3	-2.2 ^e	Ovary	10.3	-1.6 ^e
Stomach	9.1	-1.5 ^e	Stomach	7.8	-1.6 ^e	Leukemia	10.0	-1.4
Asian/Pacific Islander			American Indian/Alaska Native			Hispanic ^d		
	Rate	APC		Rate	APC		Rate	APC
All Sites	339.7	-0.6 ^e	All Sites	251.9	-2.7 ^e	All Sites	354.6	-0.4 ^e
Prostate	104.6	-1.7 ^e	Prostate	63.4	-6.8 ^e	Prostate	143.1	-0.7
Breast (Females)	92.8	1.5 ^e	Breast (Females)	60.7	-3.5 ^e	Breast (Females)	88.2	0.6
Colon and Rectum	47.0	-0.3	Lung and Bronchus	36.3	-4.2 ^e	Colon and Rectum	38.9	-0.1
Lung and Bronchus	42.8	-1.1 ^e	Colon and Rectum	36.0	-1.8	Lung and Bronchus	33.4	-1.8 ^e
Stomach	17.4	-3.3 ^e	Kidney and Renal Pelvis	11.3	-4.4 ^e	Cervix Uteri	17.3	-3.3 ^e
Corpus and Uterus, NOS	17.0	1.6 ^e	Stomach	10.8	2.6	Corpus and Uterus, NOS	16.6	0.7
Liver & IBD ^f	13.8	0.6	Corpus and Uterus, NOS	10.1	-	Non-Hodgkin Lymphoma	16.1	-0.4
Non-Hodgkin Lymphoma	13.7	0.6	Ovary	8.9	-	Stomach	13.5	-1.7 ^e
Cervix Uteri	10.5	-4.9 ^e	Non-Hodgkin Lymphoma	8.2	1.8	Ovary	11.9	0.2
Ovary	10.4	0.3	Pancreas	7.5	-	Urinary Bladder	10.8	-0.1
Urinary Bladder	9.7	0.1	Oral Cavity and Pharynx	7.2	-6.7 ^e	Kidney and Renal Pelvis	10.8	2.4 ^e
Pancreas	9.3	-0.5	Liver & IBD ^f	7.1	-2.7	Pancreas	10.0	-0.2
Oral Cavity and Pharynx	8.9	-1.1	Cervix Uteri	6.6	-6.9 ^e	Leukemia	9.5	-0.7
Thyroid	8.0	1.9 ^e	Leukemia	4.9	2.4	Liver & IBD ^f	8.9	3.4 ^e
Leukemia	7.8	-1.3 ^e	Urinary Bladder	4.8	-	Oral Cavity and Pharynx	6.7	-2.1 ^e

The APC is the Annual Percent Change over the time interval.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.

^c Incidence data are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

^d Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics does not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

^e The APC is significantly different from zero ($p < .05$).

^f IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

Table I-20
AGE-ADJUSTED RATES AND TRENDS^a FOR THE TOP 15 CANCER SITES^b BY RACE/ETHNICITY

SEER Cancer Incidence ^c 1992-2002								
Males								
All Races			White		Black			
	Rate	APC		Rate	APC			
All Sites	570.9	-1.3 ^e	All Sites	572.7	-1.3 ^e	All Sites	715.6	-1.7 ^e
Prostate	180.1	-2.0 ^e	Prostate	175.5	-2.1 ^e	Prostate	283.8	-1.9 ^e
Lung and Bronchus	82.7	-2.2 ^e	Lung and Bronchus	81.5	-2.1 ^e	Lung and Bronchus	122.8	-2.5 ^e
Colon and Rectum	64.0	-1.2 ^e	Colon and Rectum	63.8	-1.3 ^e	Colon and Rectum	72.9	-0.5
Urinary Bladder	36.1	-0.2	Urinary Bladder	39.7	-0.1	Oral Cavity and Pharynx	20.7	-3.1 ^e
Non-Hodgkin Lymphoma	23.7	-0.5	Non-Hodgkin Lymphoma	24.9	-0.4	Urinary Bladder	20.2	-0.2
Melanoma of the Skin	20.4	2.5 ^e	Melanoma of the Skin	24.0	2.9 ^e	Stomach	19.5	-2.8 ^e
Leukemia	16.4	-1.1 ^e	Leukemia	17.4	-1.1 ^e	Non-Hodgkin Lymphoma	18.8	-1.2
Oral Cavity and Pharynx	16.4	-1.8 ^e	Oral Cavity and Pharynx	16.2	-1.5 ^e	Kidney and Renal Pelvis	18.5	2.2 ^e
Kidney and Renal Pelvis	15.5	1.4 ^e	Kidney and Renal Pelvis	15.9	1.6 ^e	Pancreas	17.5	-2.5 ^e
Stomach	13.1	-2.1 ^e	Pancreas	12.5	0.1	Myeloma	13.5	-0.7
Pancreas	12.7	-0.4 ^e	Stomach	11.3	-2.1 ^e	Leukemia	12.9	-1.6
Liver & IBD ^f	8.6	3.0 ^e	Brain and ONS ^f	8.5	-0.4	Larynx	12.7	-3.2 ^e
Brain and ONS ^f	7.7	-0.7	Esophagus	7.4	1.5 ^e	Esophagus	12.4	-5.7 ^e
Esophagus	7.6	0.3	Larynx	7.1	-3.3 ^e	Liver & IBD ^f	10.8	4.5 ^e
Larynx	7.2	-3.3 ^e	Liver & IBD ^f	6.8	2.9 ^e	Kaposi Sarcoma	6.4	-12.7 ^e
Asian/Pacific Islander			American Indian/Alaska Native		Hispanic ^d			
	Rate	APC		Rate	APC		Rate	APC
All Sites	394.4	-1.2 ^e	All Sites	285.5	-3.8 ^e	All Sites	429.6	-0.9 ^e
Prostate	104.6	-1.7 ^e	Prostate	63.4	-6.8 ^e	Prostate	143.1	-0.7
Lung and Bronchus	61.2	-1.4 ^e	Lung and Bronchus	49.8	-5.4 ^e	Colon and Rectum	48.1	0.0
Colon and Rectum	56.9	-0.4	Colon and Rectum	40.8	-2.7	Lung and Bronchus	47.2	-2.0 ^e
Stomach	23.1	-3.3 ^e	Kidney and Renal Pelvis	15.6	-4.0 ^e	Non-Hodgkin Lymphoma	19.3	-0.9
Liver & IBD ^f	20.9	1.0	Stomach	14.6	-	Urinary Bladder	19.0	-0.2
Urinary Bladder	16.8	1.1	Oral Cavity and Pharynx	11.3	-9.2 ^e	Stomach	18.3	-2.5 ^e
Non-Hodgkin Lymphoma	16.7	0.2	Non-Hodgkin Lymphoma	9.8	2.2	Kidney and Renal Pelvis	14.7	2.0 ^e
Oral Cavity and Pharynx	12.6	-1.5	Liver & IBD ^f	9.0	-	Liver & IBD ^f	13.4	2.2 ^e
Pancreas	10.7	-2.8 ^e	Urinary Bladder	8.3	-	Leukemia	11.8	-0.6
Leukemia	9.8	-0.3	Pancreas	7.8	-	Pancreas	10.8	-0.9
Kidney and Renal Pelvis	8.7	0.1	Esophagus	6.1	-	Oral Cavity and Pharynx	10.1	-2.8 ^e
Esophagus	5.1	-2.0	Leukemia	5.5	-	Myeloma	6.5	-1.1
Myeloma	4.2	-1.4	Myeloma	4.1	-	Esophagus	5.9	-1.2
Brain and ONS ^f	4.1	-1.6	Brain and ONS ^f	3.3	-	Brain and ONS ^f	5.7	0.1
Thyroid	3.9	1.6	Gallbladder	2.9	-	Larynx	5.6	-1.6 ^e

The APC is the Annual Percent Change over the time interval.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.

^c Incidence data are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

^d Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics does not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

^e The APC is significantly different from zero ($p < .05$).

^f IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

Table I-21
AGE-ADJUSTED RATES AND TRENDS^a FOR THE TOP 15 CANCER SITES^b BY RACE/ETHNICITY

SEER Cancer Incidence ^c 1992-2002								
Females								
All Races			White		Black			
	Rate	APC		Rate	APC			
All Sites	412.1	0.1	All Sites	425.7	0.2	All Sites	401.6	-0.2
Breast	132.4	0.4	Breast	138.3	0.5	Breast	120.2	-0.2
Lung and Bronchus	49.2	-0.2	Lung and Bronchus	51.3	-0.1	Colon and Rectum	55.9	-0.1
Colon and Rectum	46.4	-0.6 ^e	Colon and Rectum	45.9	-0.7 ^e	Lung and Bronchus	53.6	0.5
Corpus and Uterus, NOS	24.4	-0.2	Corpus and Uterus, NOS	25.9	-0.3	Corpus and Uterus, NOS	18.4	1.8 ^e
Non-Hodgkin Lymphoma	15.5	0.8 ^e	Non-Hodgkin Lymphoma	16.3	0.8 ^e	Pancreas	14.7	-1.6 ^e
Ovary	14.2	-0.9 ^e	Melanoma of the Skin	15.9	3.0 ^e	Cervix Uteri	12.6	-3.8 ^e
Melanoma of the Skin	13.2	2.3 ^e	Ovary	15.1	-0.8 ^e	Non-Hodgkin Lymphoma	10.9	2.5 ^e
Pancreas	9.9	-0.3	Thyroid	10.2	5.2 ^e	Ovary	10.3	-1.6 ^e
Thyroid	9.8	4.8 ^e	Leukemia	10.1	-0.5	Myeloma	10.1	-1.8 ^e
Cervix Uteri	9.7	-2.8 ^e	Urinary Bladder	9.9	-0.2	Stomach	9.7	0.0
Leukemia	9.6	-0.8 ^e	Pancreas	9.6	-0.3	Kidney and Renal Pelvis	9.1	2.5 ^e
Urinary Bladder	9.2	-0.4 ^e	Cervix Uteri	9.3	-2.2 ^e	Leukemia	8.0	-1.2
Kidney and Renal Pelvis	7.6	1.4 ^e	Kidney and Renal Pelvis	7.9	1.5 ^e	Urinary Bladder	7.5	0.9
Oral Cavity and Pharynx	6.7	-1.1 ^e	Oral Cavity and Pharynx	6.7	-1.2 ^e	Oral Cavity and Pharynx	6.5	-1.7 ^e
Stomach	6.2	-0.7	Brain and ONS ^f	6.0	-0.1	Thyroid	5.5	4.5 ^e
Asian/Pacific Islander			American Indian/Alaska Native		Hispanic ^d			
	Rate	APC		Rate	APC			
All Sites	301.2	0.3	All Sites	229.8	-1.7 ^e	All Sites	309.0	0.1
Breast	92.8	1.5 ^e	Breast	60.7	-3.5 ^e	Breast	88.2	0.6
Colon and Rectum	39.3	0.0	Colon and Rectum	32.3	-1.0	Colon and Rectum	32.3	-0.2
Lung and Bronchus	28.4	0.0	Lung and Bronchus	25.8	-2.8 ^e	Lung and Bronchus	24.1	-1.5 ^e
Corpus and Uterus, NOS	17.0	1.6 ^e	Corpus and Uterus, NOS	10.1	-	Cervix Uteri	17.3	-3.3 ^e
Stomach	12.9	-2.9 ^e	Ovary	8.9	-	Corpus and Uterus, NOS	16.6	0.7
Thyroid	11.7	2.0 ^e	Stomach	7.9	-	Non-Hodgkin Lymphoma	13.3	0.4
Non-Hodgkin Lymphoma	11.2	1.2	Kidney and Renal Pelvis	7.9	-	Ovary	11.9	0.2
Cervix Uteri	10.5	-4.9 ^e	Pancreas	7.3	-	Stomach	10.2	-0.6
Ovary	10.4	0.3	Non-Hodgkin Lymphoma	6.9	-	Thyroid	9.7	2.9 ^e
Pancreas	8.3	2.0 ^e	Cervix Uteri	6.6	-6.9 ^e	Pancreas	9.4	0.2
Liver & IBD ^f	7.9	0.2	Thyroid	6.1	2.3	Kidney and Renal Pelvis	7.8	2.7 ^e
Leukemia	6.2	-2.2 ^e	Liver & IBD ^f	5.6	-	Leukemia	7.7	-0.6
Oral Cavity and Pharynx	5.8	-0.1	Leukemia	4.5	-	Liver & IBD ^f	5.4	5.0 ^e
Urinary Bladder	4.2	-1.3	Oral Cavity and Pharynx	4.0	-	Urinary Bladder	5.2	0.3
Kidney and Renal Pelvis	4.1	2.8 ^e	Gallbladder	3.9	-	Brain and ONS ^f	4.6	0.6

The APC is the Annual Percent Change over the time interval.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.

^c Incidence data are from the 13 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

^d Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics does not include cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

^e The APC is significantly different from zero ($p < .05$).

^f IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

Table I-22
AGE-ADJUSTED RATES AND TRENDS^a FOR THE TOP 15 CANCER SITES^b BY RACE/ETHNICITY

US Mortality^c 1992-2002
Both Sexes

All Races			White			Black		
	Rate	APC		Rate	APC		Rate	APC
All Sites	204.0	-1.0 ^e	All Sites	200.8	-0.9 ^e	All Sites	259.3	-1.5 ^e
Lung and Bronchus	57.1	-0.8 ^e	Lung and Bronchus	56.9	-0.7 ^e	Prostate	73.7	-2.5 ^e
Prostate	33.9	-3.6 ^e	Prostate	31.2	-3.7 ^e	Lung and Bronchus	66.9	-1.5 ^e
Breast (Females)	28.5	-2.4 ^e	Breast (Females)	28.0	-2.5 ^e	Breast (Females)	36.2	-1.2 ^e
Colon and Rectum	21.6	-1.8 ^e	Colon and Rectum	21.1	-1.9 ^e	Colon and Rectum	28.6	-0.8 ^e
Pancreas	10.6	-0.1	Pancreas	10.3	0.1	Pancreas	14.4	-1.1 ^e
Ovary	9.0	-0.5 ^e	Ovary	9.3	-0.4	Stomach	9.6	-2.6 ^e
Non-Hodgkin Lymphoma	8.4	-0.8	Non-Hodgkin Lymphoma	8.7	-0.8	Ovary	7.6	-0.8 ^e
Leukemia	7.7	-0.6 ^e	Leukemia	7.9	-0.5 ^e	Myeloma	7.5	-0.8 ^e
Stomach	4.9	-3.0 ^e	Brain and ONS ^f	5.0	-0.8 ^e	Esophagus	7.3	-4.1 ^e
Brain and ONS ^f	4.7	-0.9 ^e	Urinary Bladder	4.5	-0.1	Corpus and Uterus, NOS	7.0	0.2
Liver & IBD ^f	4.4	1.9 ^e	Stomach	4.4	-3.2 ^e	Leukemia	7.0	-1.0 ^e
Urinary Bladder	4.4	-0.3 ^e	Kidney and Renal Pelvis	4.3	-0.1	Cervix Uteri	6.2	-4.9 ^e
Esophagus	4.3	0.6 ^e	Liver & IBD ^f	4.1	2.0 ^e	Liver & IBD ^f	6.0	1.3 ^e
Kidney and Renal Pelvis	4.2	-0.1	Esophagus	4.1	1.6 ^e	Non-Hodgkin Lymphoma	5.7	-0.5
Corpus and Uterus, NOS	4.1	-0.1	Corpus and Uterus, NOS	3.9	-0.2	Oral Cavity and Pharynx	4.7	-4.3 ^e
Asian/Pacific Islander			American Indian/Alaska Native			Hispanic ^d		
	Rate	APC		Rate	APC		Rate	APC
All Sites	125.1	-1.7 ^e	All Sites	135.3	-0.7	All Sites	137.4	-0.6 ^e
Lung and Bronchus	28.6	-1.5 ^e	Lung and Bronchus	36.3	-0.9	Lung and Bronchus	25.5	-0.9 ^e
Prostate	14.1	-5.2 ^e	Prostate	21.5	-4.5 ^e	Prostate	24.7	-2.4 ^e
Colon and Rectum	13.5	-1.9 ^e	Breast (Females)	14.4	-1.5	Breast (Females)	17.7	-1.9 ^e
Breast (Females)	12.9	-0.6	Colon and Rectum	13.8	0.7	Colon and Rectum	14.2	-0.2
Liver & IBD ^f	10.8	-0.7	Pancreas	6.2	0.4	Pancreas	8.4	-0.1
Stomach	9.7	-3.9 ^e	Liver & IBD ^f	5.6	2.2	Stomach	7.4	-1.8 ^e
Pancreas	7.5	-0.6	Stomach	5.5	-1.1	Liver & IBD ^f	7.2	2.0 ^e
Non-Hodgkin Lymphoma	5.2	-1.7 ^e	Ovary	5.1	-0.4	Non-Hodgkin Lymphoma	6.5	-0.6
Ovary	4.8	0.0	Kidney and Renal Pelvis	4.9	0.6	Ovary	6.2	-0.6
Leukemia	4.3	-1.4	Non-Hodgkin Lymphoma	4.4	2.1	Leukemia	5.3	-0.1
Cervix Uteri	2.9	-3.3 ^e	Leukemia	4.1	-1.8	Cervix Uteri	3.8	-3.0 ^e
Oral Cavity and Pharynx	2.5	-2.4 ^e	Cervix Uteri	3.2	-4.7 ^e	Kidney and Renal Pelvis	3.8	0.4
Corpus and Uterus, NOS	2.2	1.4	Myeloma	2.9	-0.5	Corpus and Uterus, NOS	3.2	0.6
Esophagus	2.1	-3.3 ^e	Esophagus	2.7	2.6 ^e	Myeloma	3.2	1.4
Brain and ONS ^f	1.9	0.1	Corpus and Uterus, NOS	2.6	0.3	Brain and ONS ^f	2.9	0.6

The APC is the Annual Percent Change over the time interval.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.

^c Mortality data are analyzed from a public use file provided by the National Center for Health Statistics (NCHS).

^d Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Mortality data for Hispanics does not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

^e The APC is significantly different from zero ($p < .05$).

^f IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

Table I-23
AGE-ADJUSTED RATES AND TRENDS^a FOR THE TOP 15 CANCER SITES^b BY RACE/ETHNICITY

			US Mortality ^c 1992-2002					
			Males					
All Races			White		Black			
	Rate	APC		Rate	APC		Rate	APC
All Sites	258.6	-1.5 ^e	All Sites	252.5	-1.4 ^e	All Sites	360.5	-2.0 ^e
Lung and Bronchus	80.8	-1.9 ^e	Lung and Bronchus	79.3	-1.7 ^e	Lung and Bronchus	109.1	-2.5 ^e
Prostate	33.9	-3.6 ^e	Prostate	31.2	-3.7 ^e	Prostate	73.7	-2.5 ^e
Colon and Rectum	26.3	-2.0 ^e	Colon and Rectum	25.8	-2.2 ^e	Colon and Rectum	34.8	-0.8 ^e
Pancreas	12.3	-0.3 ^e	Pancreas	12.0	0.0	Pancreas	16.4	-1.5 ^e
Non-Hodgkin Lymphoma	10.4	-0.7	Non-Hodgkin Lymphoma	10.8	-0.7	Stomach	14.1	-3.0 ^e
Leukemia	10.4	-0.7 ^e	Leukemia	10.6	-0.6 ^e	Esophagus	12.9	-4.4 ^e
Urinary Bladder	7.7	-0.6 ^e	Urinary Bladder	8.0	-0.5 ^e	Leukemia	9.3	-1.1 ^e
Esophagus	7.6	0.6 ^e	Esophagus	7.2	1.6 ^e	Liver & IBD ^f	9.2	1.3 ^e
Stomach	7.1	-3.4 ^e	Stomach	6.3	-3.6 ^e	Myeloma	9.1	-1.2 ^e
Liver & IBD ^f	6.5	2.1 ^e	Kidney and Renal Pelvis	6.2	-0.1	Oral Cavity and Pharynx	8.2	-4.6 ^e
Kidney and Renal Pelvis	6.2	-0.1	Brain and ONS ^f	6.1	-0.7 ^e	Non-Hodgkin Lymphoma	7.4	-0.6
Brain and ONS ^f	5.7	-0.7 ^e	Liver & IBD ^f	5.9	2.1 ^e	Kidney and Renal Pelvis	6.2	0.1
Myeloma	4.8	-0.5 ^e	Myeloma	4.5	-0.3	Urinary Bladder	5.9	-2.0 ^e
Oral Cavity and Pharynx	4.5	-2.7 ^e	Melanoma of the Skin	4.4	0.0	Larynx	5.7	-2.9 ^e
Melanoma of the Skin	3.9	-0.1	Oral Cavity and Pharynx	4.2	-2.3 ^e	Brain and ONS ^f	3.3	-0.8 ^e
			American Indian/Alaska Native			Hispanic ^d		
	Rate	APC		Rate	APC		Rate	APC
All Sites	155.7	-2.0 ^e	All Sites	165.5	-1.2	All Sites	175.7	-0.9 ^e
Lung and Bronchus	41.1	-1.9 ^e	Lung and Bronchus	50.0	-2.3	Lung and Bronchus	40.4	-1.5 ^e
Colon and Rectum	16.4	-1.5 ^e	Prostate	21.5	-4.5 ^e	Prostate	24.7	-2.4 ^e
Liver & IBD ^f	15.9	-0.6	Colon and Rectum	16.1	1.7	Colon and Rectum	17.9	-0.4
Prostate	14.1	-5.2 ^e	Liver & IBD ^f	7.6	1.6	Liver & IBD ^f	10.2	1.6 ^e
Stomach	12.6	-3.9 ^e	Stomach	7.4	-1.7	Stomach	10.0	-2.1 ^e
Pancreas	8.4	-2.1 ^e	Kidney and Renal Pelvis	6.8	0.8	Pancreas	9.4	-0.8
Non-Hodgkin Lymphoma	6.6	-2.2 ^e	Pancreas	6.3	1.4	Non-Hodgkin Lymphoma	8.0	-1.1
Leukemia	5.4	-1.1	Leukemia	5.1	-3.3	Leukemia	6.7	0.2
Oral Cavity and Pharynx	3.8	-2.8 ^e	Non-Hodgkin Lymphoma	5.1	1.1	Kidney and Renal Pelvis	5.5	0.7
Esophagus	3.6	-3.7 ^e	Esophagus	4.8	1.5	Esophagus	4.5	-1.2 ^e
Urinary Bladder	2.9	0.6	Oral Cavity and Pharynx	3.6	-1.5	Urinary Bladder	4.2	-0.7
Kidney and Renal Pelvis	2.7	-0.2	Myeloma	3.3	-	Myeloma	3.8	1.1
Brain and ONS ^f	2.4	3.0 ^e	Urinary Bladder	2.5	-	Brain and ONS ^f	3.5	0.5
Myeloma	2.2	-2.4	Brain and ONS ^f	2.4	0.9	Oral Cavity and Pharynx	3.2	-4.0 ^e
Soft Tissue including Heart	1.1	-4.4 ^e	Larynx	1.9	-	Larynx	2.2	-3.2 ^e

The APC is the Annual Percent Change over the time interval.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.

^c Mortality data are analyzed from a public use file provided by the National Center for Health Statistics (NCHS).

^d Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Mortality data for Hispanics does not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

^e The APC is significantly different from zero ($p < .05$).

^f IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

Table I-24
AGE-ADJUSTED RATES AND TRENDS^a FOR THE TOP 15 CANCER SITES^b BY RACE/ETHNICITY

US Mortality^c 1992-2002
Females

All Races			White			Black		
	Rate	APC		Rate	APC		Rate	APC
All Sites	169.2	-0.7 ^e	All Sites	167.9	-0.7 ^e	All Sites	199.2	-0.8 ^e
Lung and Bronchus	40.3	0.6 ^e	Lung and Bronchus	41.1	0.7 ^e	Lung and Bronchus	39.3	0.4 ^e
Breast	28.5	-2.4 ^e	Breast	28.0	-2.5 ^e	Breast	36.2	-1.2 ^e
Colon and Rectum	18.3	-1.8 ^e	Colon and Rectum	17.8	-1.9 ^e	Colon and Rectum	24.7	-0.9 ^e
Pancreas	9.2	-0.1	Ovary	9.3	-0.4	Pancreas	12.9	-0.8 ^e
Ovary	9.0	-0.5 ^e	Pancreas	8.9	0.0	Ovary	7.6	-0.8 ^e
Non-Hodgkin Lymphoma	6.8	-0.9	Non-Hodgkin Lymphoma	7.1	-0.9	Corpus and Uterus, NOS	7.0	0.2
Leukemia	5.9	-0.6 ^e	Leukemia	6.0	-0.5 ^e	Stomach	6.7	-2.1 ^e
Corpus and Uterus, NOS	4.1	-0.1	Brain and ONS ^f	4.1	-1.0 ^e	Myeloma	6.5	-0.5
Brain and ONS ^f	3.8	-1.1 ^e	Corpus and Uterus, NOS	3.9	-0.2	Cervix Uteri	6.2	-4.9 ^e
Stomach	3.4	-2.6 ^e	Stomach	3.0	-2.9 ^e	Leukemia	5.5	-0.7 ^e
Myeloma	3.2	-0.4	Myeloma	2.9	-0.4 ^e	Non-Hodgkin Lymphoma	4.5	-0.3
Cervix Uteri	3.0	-3.1 ^e	Kidney and Renal Pelvis	2.9	-0.4	Liver & IBD ^f	3.7	0.7
Liver & IBD ^f	2.9	1.2 ^e	Cervix Uteri	2.7	-2.7 ^e	Esophagus	3.5	-3.3 ^e
Kidney and Renal Pelvis	2.8	-0.4	Liver & IBD ^f	2.7	1.1 ^e	Urinary Bladder	3.0	-0.6
Urinary Bladder	2.3	-0.4	Urinary Bladder	2.3	-0.3	Kidney and Renal Pelvis	2.8	0.0

Asian/Pacific Islander			American Indian/Alaska Native			Hispanic ^d		
	Rate	APC		Rate	APC		Rate	APC
All Sites	102.3	-1.1 ^e	All Sites	115.2	-0.3	All Sites	112.1	-0.4 ^e
Lung and Bronchus	19.0	-0.4	Lung and Bronchus	26.4	1.0	Breast	17.7	-1.9 ^e
Breast	12.9	-0.6	Breast	14.4	-1.5	Lung and Bronchus	14.9	0.1
Colon and Rectum	11.3	-2.2 ^e	Colon and Rectum	12.1	-0.2	Colon and Rectum	11.5	0.1
Stomach	7.5	-3.5 ^e	Pancreas	6.1	0.1	Pancreas	7.6	0.2
Pancreas	6.7	0.9	Ovary	5.1	-0.4	Ovary	6.2	-0.6
Liver & IBD ^f	6.5	-0.7	Stomach	4.2	0.0	Stomach	5.5	-1.5 ^e
Ovary	4.8	0.0	Liver & IBD ^f	4.1	1.7	Non-Hodgkin Lymphoma	5.3	0.1
Non-Hodgkin Lymphoma	4.1	-0.9	Non-Hodgkin Lymphoma	3.8	2.4	Liver & IBD ^f	4.8	2.1 ^e
Leukemia	3.4	-1.6	Kidney and Renal Pelvis	3.4	-1.1	Leukemia	4.3	-0.6
Cervix Uteri	2.9	-3.3 ^e	Leukemia	3.4	-1.2	Cervix Uteri	3.8	-3.0 ^e
Corpus and Uterus, NOS	2.2	1.4	Cervix Uteri	3.2	-4.7 ^e	Corpus and Uterus, NOS	3.2	0.6
Brain and ONS ^f	1.6	-3.3 ^e	Myeloma	2.7	-	Myeloma	2.7	1.4
Myeloma	1.6	1.7	Corpus and Uterus, NOS	2.6	0.3	Brain and ONS ^f	2.5	0.6
Oral Cavity and Pharynx	1.5	-1.2	Gallbladder	1.7	-	Kidney and Renal Pelvis	2.4	-0.5
Kidney and Renal Pelvis	1.2	0.3	Brain and ONS ^f	1.6	-	Gallbladder	1.8	-3.2 ^e

The APC is the Annual Percent Change over the time interval.

- Statistic not shown. Rate based on less than 25 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Top 15 cancer sites selected based on 1992-2002 age-adjusted rates for the race/ethnic group.

^c Mortality data are analyzed from a public use file provided by the National Center for Health Statistics (NCHS).

^d Hispanic is not mutually exclusive from Whites, Blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Mortality data for Hispanics does not include cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma and Vermont.

^e The APC is significantly different from zero ($p < .05$).

^f IHBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

Surveillance, Epidemiology, and End Results Program, 2005

National Cancer Institute

U.S.A




Figure I-1

^a Data not used in Cancer Statistics Review calculations.

* Greater California is the state of California excluding San Francisco/Oakland, San Jose/Monterey and Los Angeles areas.

<http://seer.cancer.gov>

Leading Causes of Death in US Percent of All Causes of Death 1975 vs 2002





Figure 1-2

Source: NCHS public use data file for the total US.

US Death Rates 1975-2002

Ages Less Than 65



Ages 65 and Over





Figure 1-3

Source: NCHS public use data file for the total US. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Trends in SEER Incidence & US Death Rates by Primary Cancer Site 1992-2002

Trends in SEER Incidence Rates



Trends in US Cancer Death Rates




Figure 1-4

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia) and NCHS public use data file for the total US.

Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

The APC is the Annual Percent Change over the time interval.

* The APC is significantly different from zero ($p < .05$).

Trends in SEER Incidence Rates by Primary Cancer Site 1992-2002




Figure 1-5

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

The APC is the Annual Percent Change over the time interval.

* The APC is significantly different from zero ($p < .05$).

Trends in US Death Rates by Primary Cancer Site 1992-2002




Figure 1-6

Source: NCHS public use data file for the total US.
 Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 The APC is the Annual Percent Change over the time interval.
 * The APC is significantly different from zero ($p < .05$).

Trends in SEER Incidence Rates by Primary Cancer Site 1992-2002




Figure 1-7

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia).

Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

The APC is the Annual Percent Change over the time interval.

* The APC is significantly different from zero ($p < .05$).

Trends in US Death Rates by Primary Cancer Site 1992-2002




Figure 1-8

Source: NCHS public use data file for the total US.

Underlying rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

The APC is the Annual Percent Change over the time interval.

* The APC is significantly different from zero ($p < .05$).

SEER Incidence* and US Death Rates,# 1998-2002 5-Year Relative Survival Rates,^ 1995-2001 All Cancer Combined, by Race and Sex





Figure 1-9


* Incidence rates are from the SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia) and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 # Death rates are from the NCHS public use data file for the total US and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 ^ Survival rates are from the SEER 9 areas. Relative survival rates are expressed as percents.

Trends in US Death Rates, 1992-2002 by Primary Cancer Site All Ages, by Race



Source: NCHS public use data file for the total US.
 The APC is the Annual Percent Change over the time interval.
 Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

5-Year Relative Survival Rates SEER Program, 1995-2001 Both Sexes, by Race




Source: SEER 9 areas.

Figure I-12


SEER Cancer Incidence and US Death Rates, 1998-2002 By Cancer Site and Race

Incidence Cancer Site Mortality


Lung and Bronchus




Colon and Rectum



Breast (Female)



Prostate



Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia) and NCHS public use data file for the total US. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics excludes cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia. Mortality data for Hispanics excludes cases from Connecticut, Maine, Maryland, Minnesota, Oklahoma, New Hampshire, New York, North Dakota, and Vermont.

SEER Incidence 1992-2002 Males by Race/Ethnicity




Figure 1-13

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Incidence data for Hispanics excludes cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.

API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native.

^^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

SEER Incidence 1992-2002 Females by Race/Ethnicity




Figure I-14

Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Incidence data for Hispanics excludes cases from Detroit, Hawaii, Alaska Native Registry and Rural Georgia.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.

API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native.

^^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

US Mortality 1992-2002 Males by Race/Ethnicity




Figure I-15

Source: NCHS public use data file for the total US. Mortality data for Hispanics excludes cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

Regression lines are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native.

^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

US Mortality 1992-2002 Females by Race/Ethnicity




Figure 1-16

Source: NCHS public use data file for the total US. Mortality data for Hispanics excludes cases from Connecticut, Maine, Maryland, Minnesota, New Hampshire, New York, North Dakota, Oklahoma, and Vermont.

Regression lines are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

API = Asian/Pacific Islander. AI/AN = American Indian/Alaska Native.

^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence Percent Change, 1992-2002

Numbers (burden) vs Rates (risk)

All Ages




Figure I-17

US Incidence estimates based on SEER age-specific rates applied to US population.

Mortality Percent Change, 1992-2002

Numbers (burden) vs Rates (risk)

All Ages





Figure I-18

US Mortality estimates based on US age-specific rates applied to US population.

Person-Years of Life Lost Due to Cancer, All Races Both Sexes, 2002



Average Years of Life Lost Per Person Dying of Cancer All Races, Both Sexes, 2002





Figure I-19

Source: NCHS public use data file for the total US and 2002 Life Tables.

Person-Years of Life Lost Due to Major Causes of Death in US All Races, Both Sexes, 2002



Average Years of Life Lost Per Person Due to Major Causes of Death in US All Races, Both Sexes, 2002




Figure I-20

Source: NCHS public use data file for the total US and 2002 Life Tables.
* Human Immunodeficiency Virus

SEER Incidence and Delay Adjusted Incidence Rates+ All Cancer Sites, By Sex




Figure I-21

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero ($p < 0.05$).

SEER Incidence and Delay Adjusted Incidence Rates+ Both Sexes






Figure 1-22

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.

* The APC is significantly different from zero ($p < 0.05$).

SEER Incidence and Delay Adjusted Incidence Rates⁺ Males



+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
* The APC is significantly different from zero ($p < 0.05$).

Figure 1-23

SEER Incidence and Delay Adjusted Incidence Rates⁺ Females





Figure I-24

+ Source: SEER 9 areas. Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 Regression lines and the APCs are calculated using the Joinpoint Regression Program Version 3.0, April 2005, National Cancer Institute.
 The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
 * The APC is significantly different from zero ($p < 0.05$).

Partition of Trend in Incidence Rates for the Time Period 1992-2002 All Races, Both Sexes


Overall Decreasing Regression Coefficient : -2.75



Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Percents may not add to 100 due to rounding.

Partition of Trend in Incidence Rates for the Time Period 1992-2002 All Races, Males


Overall Decreasing Regression Coefficient : -7.90



Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Percents may not add to 100 due to rounding.

Partition of Trend in Incidence Rates for the Time Period 1992-2002 All Races, Females


Overall Increasing Regression Coefficient : 0.28



Source: SEER 13 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Percents may not add to 100 due to rounding.

Partition of Trend in Death Rates for the Time Period 1992-2002 All Races, Both Sexes


Overall Decreasing Regression Coefficient : -2.13



Source: NCHS public-use file for the total US.
Percents may not add to 100 due to rounding.

Partition of Trend in Death Rates for the Time Period 1992-2002 All Races, Males


Overall Decreasing Regression Coefficient : -3.87



Source: NCHS public-use file for the total US.
Percents may not add to 100 due to rounding.

Partition of Trend in Death Rates for the Time Period 1992-2002 All Races, Females

Overall Decreasing Regression Coefficient : -1.26



Source: NCHS public-use file for the total US.
Percents may not add to 100 due to rounding.